dmp_title,md_path,Element title,Generated_Llama_content,status
Clinical and MRI data from human research participants,primary\llama-DMPs\Clinical and MRI data from human research participants-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"The proposed study will generate demographic, clinical, MRI, 1H fMRS, and fMRI imaging data from 110 affected youth and 110 matched healthy controls. The estimated amount of data includes: 
     - Demographic data: 220 subjects x approximately 50 variables per subject = 11,000 data points.
     - Clinical data: 220 subjects x approximately 100 variables per subject (including questionnaires, assessments) = 22,000 data points.
     - MRI, 1H fMRS, and fMRI imaging data: Approximately 660 scans (3 types of scans per 220 subjects), with each scan producing several gigabytes of data. The total estimated size for imaging data is around 2.2 terabytes.",ok
Clinical and MRI data from human research participants,primary\llama-DMPs\Clinical and MRI data from human research participants-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All collected data (demographic, clinical, MRI, 1H fMRS, and fMRI) will be preserved and shared because they are crucial for understanding mental health conditions in youth. Sharing these data will facilitate replication studies, meta-analyses, and the development of new hypotheses, thereby advancing our knowledge of mental health disorders and improving treatment outcomes.",ok
Clinical and MRI data from human research participants,primary\llama-DMPs\Clinical and MRI data from human research participants-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","The following metadata and documentation will be made accessible:
     - Study protocols
     - Data collection instruments (e.g., questionnaires)
     - MRI scanning protocols
     - Data processing and analysis pipelines
     - Informed consent forms",ok
Clinical and MRI data from human research participants,primary\llama-DMPs\Clinical and MRI data from human research participants-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools and software needed to access or manipulate shared scientific data include:
     - MRI scan analysis software (e.g., FSL, AFNI)
     - Statistical analysis software (e.g., R, Python libraries such as pandas, numpy)
     - Data management platforms for organizing and sharing large datasets.",ok
Clinical and MRI data from human research participants,primary\llama-DMPs\Clinical and MRI data from human research participants-llama3.3.md,### Element 3: Standards:,"The following common data standards will be applied to ensure interoperability of datasets and resources:
     - NIMH Data Archive (NDA) standards for clinical and demographic data
     - BIDS (Brain Imaging Data Structure) standard for MRI, 1H fMRS, and fMRI imaging data",ok
Clinical and MRI data from human research participants,primary\llama-DMPs\Clinical and MRI data from human research participants-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,The NIMH Data Archive (NDA) has been selected as the repository for archiving scientific data and metadata arising from this project.,ok
Clinical and MRI data from human research participants,primary\llama-DMPs\Clinical and MRI data from human research participants-llama3.3.md,2. **How scientific data will be findable and identifiable:**,"Scientific data will be made findable and identifiable through a persistent unique identifier provided by the NDA, ensuring that each dataset can be located and accessed easily.",ok
Clinical and MRI data from human research participants,primary\llama-DMPs\Clinical and MRI data from human research participants-llama3.3.md,3. **When and how long the scientific data will be made available:**,"The scientific data will be made available to other users no later than the time of an associated publication or end of the performance period, whichever comes first. Data will remain available indefinitely through the NDA, in accordance with their data retention policies.",ok
Clinical and MRI data from human research participants,primary\llama-DMPs\Clinical and MRI data from human research participants-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","Given that all participants are consented for broad data sharing, there are no anticipated limitations on access, distribution, or reuse of the scientific data beyond standard protections for privacy and confidentiality.",ok
Clinical and MRI data from human research participants,primary\llama-DMPs\Clinical and MRI data from human research participants-llama3.3.md,2. **Whether access to scientific data will be controlled:**,"Access to the scientific data will not be controlled; once archived in the NDA, the data will be available to all registered users without need for approval, consistent with the NDA’s open-access policy.",ok
Clinical and MRI data from human research participants,primary\llama-DMPs\Clinical and MRI data from human research participants-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","To protect participant privacy, rights, and confidentiality:
     - All data will be de-identified before submission to the NDA.
     - A Certificate of Confidentiality will be obtained from the NIH to further safeguard against disclosure of identifiable information.",ok
Clinical and MRI data from human research participants,primary\llama-DMPs\Clinical and MRI data from human research participants-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be monitored and managed by the Principal Investigator (PI) and a designated data manager at our institution. The plan will be reviewed annually, or as needed, to ensure adherence to the outlined policies and procedures for data management and sharing. Regular check-ins between the PI, data manager, and other key personnel involved in data collection and analysis will help maintain oversight and address any issues that may arise during the project.",ok
Genomic data from human research participants,primary\llama-DMPs\Genomic data from human research participants-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"Our genomic study aims to generate raw whole genome sequencing data and derived data from approximately 500 research subjects. Additionally, we will collect extensive phenotypic and clinical data using standardized data dictionaries provided by the National Institute of Mental Health Data Archive (NDA). The estimated amount of data includes over 1 terabyte of genomic data and thousands of data points related to phenotypic and clinical information.",ok
Genomic data from human research participants,primary\llama-DMPs\Genomic data from human research participants-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All raw whole genome sequencing data, derived genomic data, and associated phenotypic and clinical data collected from research participants will be preserved and shared through dbGaP and NDA. The rationale for this decision is to contribute significantly to the understanding of mental health disorders by making these valuable datasets available to the broader scientific community, facilitating collaborative research, replication studies, and accelerating discovery.",ok
Genomic data from human research participants,primary\llama-DMPs\Genomic data from human research participants-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","To facilitate interpretation and reuse of our scientific data, we will make accessible comprehensive metadata including but not limited to: study protocols, data collection instruments, informed consent documents, and detailed descriptions of the genomic and phenotypic/clinical data collection processes. Additionally, data dictionaries used for organizing and structuring the phenotypic and clinical data will be shared through NDA.",ok
Genomic data from human research participants,primary\llama-DMPs\Genomic data from human research participants-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools and software such as those used for whole genome sequencing analysis (e.g., BWA, GATK) and data manipulation (e.g., Python libraries like Pandas and NumPy) will be necessary to access or manipulate shared scientific data. These tools are widely available in the scientific community and can be accessed through their respective official websites or repositories (e.g., GitHub).",ok
Genomic data from human research participants,primary\llama-DMPs\Genomic data from human research participants-llama3.3.md,### Element 3: Standards:,"To enable interoperability of datasets, we will apply common data standards for genomic data as recommended by dbGaP and for phenotypic/clinical data as specified by NDA. Specifically, we will adhere to the Human Genome Variation Society (HGVS) nomenclature guidelines for genomic variations and utilize standardized vocabularies and ontologies endorsed by NDA for clinical and phenotypic data. This application of standardized formats ensures that our datasets can be easily integrated with other studies, promoting comparative analyses and collaborative research.",ok
Genomic data from human research participants,primary\llama-DMPs\Genomic data from human research participants-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,"The raw whole genome sequencing data and derived genomic data will be submitted to dbGaP, while the phenotypic and clinical data along with associated metadata will be deposited into the National Institute of Mental Health Data Archive (NDA). Both repositories are recognized by NIH for archiving and sharing scientific data.",ok
Genomic data from human research participants,primary\llama-DMPs\Genomic data from human research participants-llama3.3.md,2. **How scientific data will be findable and identifiable:**,"Each dataset will be assigned a unique identifier by dbGaP and NDA upon submission, ensuring that our scientific data can be easily located and accessed through these repositories. Furthermore, we will utilize standard indexing tools and keywords to enhance the discoverability of our datasets.",ok
Genomic data from human research participants,primary\llama-DMPs\Genomic data from human research participants-llama3.3.md,3. **When and how long the scientific data will be made available:**,"In accordance with NIH policies, our scientific data will be made available no later than the time of publication of the main findings or at the end of the performance period, whichever comes first. The data will remain accessible through dbGaP and NDA for a minimum of 10 years after the project's completion to allow for extended research and analysis opportunities.",ok
Genomic data from human research participants,primary\llama-DMPs\Genomic data from human research participants-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","Given that all research participants will provide broad consent for data sharing, the primary factors affecting subsequent access will be related to ensuring compliance with NIH guidelines and protecting participant privacy. There are no anticipated limitations on data sharing beyond standard protections for human subjects' confidentiality.",ok
Genomic data from human research participants,primary\llama-DMPs\Genomic data from human research participants-llama3.3.md,2. **Whether access to scientific data will be controlled:**,"Access to our datasets through dbGaP and NDA may involve a controlled-access process, where researchers must apply and justify their intended use of the data before being granted access. This is particularly relevant for sensitive human subject data and ensures that data are used responsibly and ethically.",ok
Genomic data from human research participants,primary\llama-DMPs\Genomic data from human research participants-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","To safeguard the privacy, rights, and confidentiality of our research participants, we will implement rigorous de-identification procedures for all shared data. Additionally, we will obtain Certificates of Confidentiality from NIH to further protect against compelled disclosure of identifiable information. All personnel involved in the project will undergo training on human subjects' protection and confidentiality.",ok
Genomic data from human research participants,primary\llama-DMPs\Genomic data from human research participants-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be monitored by our institution's Data Management Oversight Committee, which includes representatives from our research team, the Office of Research Administration, and the Institutional Review Board (IRB). This committee will meet quarterly to review progress in data collection, sharing, and protection of human subjects' information. The Principal Investigator will be responsible for ensuring that all aspects of the Plan are implemented as described and for reporting any deviations or issues to the oversight committee.",ok
Genomic data from a non-human source,primary\llama-DMPs\Genomic data from a non-human source-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"The proposed project aims to generate a comprehensive spatially mapped single-cell atlas of the developing mouse brain. The primary deliverables include matrices of cells × (counts in peaks for ATAC, UMIs in genes for RNA, or methylation status for DNAm) along with dense metadata tables. These tables will contain detailed information for each cell, such as animal sex, developmental time point, punch of origin with x,y,z coordinates, assigned cluster and inferred cell type, and various quality control metrics (e.g., total reads, passing reads, TSS enrichment). The amount of data generated is expected to be substantial, given the complexity and depth of single-cell analyses. Initial estimates suggest terabytes of raw sequencing data, which will be processed and analyzed to produce the final datasets.",ok
Genomic data from a non-human source,primary\llama-DMPs\Genomic data from a non-human source-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All primary matrices and associated metadata tables from the mouse studies will be preserved and shared. The rationale for sharing these data is to contribute significantly to the scientific community's understanding of brain development at the single-cell level, facilitating further research into neurological disorders and developmental biology. Sharing these comprehensive datasets will enable other researchers to explore hypotheses that might not be feasible within the scope of our project, thereby accelerating discovery.",ok
Genomic data from a non-human source,primary\llama-DMPs\Genomic data from a non-human source-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","Metadata will include but is not limited to cell identifiers, experimental conditions (e.g., sequencing platform, date of preparation), and quality control metrics. Other relevant data may encompass intermediate processing files necessary for reproducing the analyses. Associated documentation will comprise study protocols, data collection instruments, and detailed methodologies used in data generation and analysis. This comprehensive set of information will facilitate the interpretation and reuse of the shared scientific data.",ok
Genomic data from a non-human source,primary\llama-DMPs\Genomic data from a non-human source-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools, software, and code are indeed necessary for accessing or manipulating the shared scientific data. Specifically, programming languages like Python and R, along with libraries such as Scanpy for single-cell analysis, will be essential. Additionally, utilization of software packages for peak calling (e.g., MACS2 for ATAC-seq) and methylation analysis tools will be required. These tools are widely used in the bioinformatics community and can be accessed through public repositories like GitHub or Bioconda.",ok
Genomic data from a non-human source,primary\llama-DMPs\Genomic data from a non-human source-llama3.3.md,### Element 3: Standards:,"The project will apply common data standards to ensure interoperability of datasets and resources. Specifically, we will adhere to the standards set by the Human Cell Atlas (HCA) for single-cell data, including the use of H5AD files for storing processed single-cell data and the implementation of FAIR (Findable, Accessible, Interoperable, Reusable) principles for metadata. For genomics data, compliance with the Genome Analysis Toolkit (GATK) best practices will be maintained. The application of these standards will facilitate the integration of our dataset with existing resources and enable seamless collaboration and comparison across studies.",ok
Genomic data from a non-human source,primary\llama-DMPs\Genomic data from a non-human source-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,Scientific data and metadata arising from this project will be archived in publicly accessible repositories such as the Gene Expression Omnibus (GEO) for genomic data and the Single Cell Portal for single-cell datasets. These repositories are compliant with NIH's guidelines for data sharing and provide a robust infrastructure for data preservation and access.,ok
Genomic data from a non-human source,primary\llama-DMPs\Genomic data from a non-human source-llama3.3.md,2. **How scientific data will be findable and identifiable:**,"Each dataset will be assigned a unique identifier, such as an accession number provided by the repository where it is archived (e.g., GEO Series or GSE number). Additionally, we will utilize standard indexing tools like DOI (Digital Object Identifier) for datasets and publications to enhance discoverability.",ok
Genomic data from a non-human source,primary\llama-DMPs\Genomic data from a non-human source-llama3.3.md,3. **When and how long the scientific data will be made available:**,"The scientific data will be made available no later than the time of publication of the main findings or at the end of the performance period, whichever comes first. The data will remain accessible indefinitely, as per the policies of the chosen repositories, to support ongoing research and future discoveries.",ok
Genomic data from a non-human source,primary\llama-DMPs\Genomic data from a non-human source-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","The primary consideration for our project is ensuring that all shared data are de-identified and do not pose any risk to privacy or confidentiality, especially since some aspects of the study may involve human cells in later phases. However, given the initial focus on mouse models, these concerns will be revisited and updated as necessary upon expansion to human cell studies.",ok
Genomic data from a non-human source,primary\llama-DMPs\Genomic data from a non-human source-llama3.3.md,2. **Whether access to scientific data will be controlled:**,Access to the scientific data generated from this project will not be controlled beyond what is required for privacy protection and compliance with regulatory standards. All datasets will be made openly accessible through public repositories.,ok
Genomic data from a non-human source,primary\llama-DMPs\Genomic data from a non-human source-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","Although the initial phase focuses on mouse models, in the event that human cell data are generated during the project (as indicated may happen based on results from the mouse studies), strict measures will be taken to protect participant privacy, including de-identification of samples, obtaining appropriate informed consent for data sharing, and potentially utilizing Certificates of Confidentiality to safeguard sensitive information.",ok
Genomic data from a non-human source,primary\llama-DMPs\Genomic data from a non-human source-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be overseen by the project's Principal Investigator (PI), in collaboration with the institution's Office of Research Compliance and the designated Data Manager. Regular reviews (at least annually) will ensure that all data are properly archived, shared according to the plan, and that any updates or changes to the plan are appropriately documented and communicated to NIH. The PI will be responsible for reporting on plan compliance as part of progress reports and will work closely with the research team to address any issues or concerns related to data management and sharing.",ok
Secondary data analysis,primary\llama-DMPs\Secondary data analysis-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"This project involves secondary data analysis of existing MRI images and clinical assessments from human research participants, along with the deposition of privately held data into a public repository. The existing data includes collections from the NIMH Data Archive (NDA) - specifically collections 2134 with 148 subjects and 2433 with 47 subjects. Additionally, we have data from a previous study involving 155 research participants with major depressive disorder that will be uploaded to the NDA during the second quarter of the first year of funding. The structural MRI scans are available for time points before and after treatment, along with relevant clinical data.",ok
Secondary data analysis,primary\llama-DMPs\Secondary data analysis-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All scientific data from this project, including MRI images and clinical assessments, will be preserved and shared through the NIMH Data Archive (NDA). The rationale for sharing these data is to contribute to the broader research community's understanding of major depressive disorder, facilitate further research, and enhance the reproducibility of findings. Sharing these data aligns with the principles of transparency and collaboration in scientific research.",ok
Secondary data analysis,primary\llama-DMPs\Secondary data analysis-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","To facilitate interpretation of the shared scientific data, we will also make accessible the following metadata and documentation: study protocols, data collection instruments, participant consent forms, and detailed descriptions of MRI acquisition parameters. These will be provided in a format that is easily understandable and usable by other researchers.",ok
Secondary data analysis,primary\llama-DMPs\Secondary data analysis-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools and software are needed to access or manipulate the shared scientific data, specifically those capable of handling MRI images (e.g., FSL, AFNI) and statistical analysis software (e.g., R, Python libraries such as Pandas and NumPy). These tools are widely available in the research community, and detailed instructions on how to access and use them will be provided alongside the shared data.",ok
Secondary data analysis,primary\llama-DMPs\Secondary data analysis-llama3.3.md,### Element 3: Standards:,"To enable interoperability of datasets and resources, we will apply common data standards to the scientific data and associated metadata. Specifically, we will adhere to the BIDS (Brain Imaging Data Structure) standard for organizing and describing MRI data, and use standardized clinical data elements where applicable. These standards are widely recognized in the field and facilitate the integration of our data with other datasets.",ok
Secondary data analysis,primary\llama-DMPs\Secondary data analysis-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,"The scientific data and metadata arising from this project will be archived in the NIMH Data Archive (NDA), a repository that is widely recognized for its role in storing and sharing mental health research data.",ok
Secondary data analysis,primary\llama-DMPs\Secondary data analysis-llama3.3.md,2. **How scientific data will be findable and identifiable:**,"The scientific data will be made findable and identifiable through the use of persistent unique identifiers (e.g., DOI - Digital Object Identifier) and standard indexing tools provided by the NDA, allowing other researchers to easily locate and access our shared data.",ok
Secondary data analysis,primary\llama-DMPs\Secondary data analysis-llama3.3.md,3. **When and how long the scientific data will be made available:**,"The scientific data will be made available to other users no later than the time of an associated publication or end of the performance period, whichever comes first. The data will remain available indefinitely through the NDA, subject to any limitations imposed by considerations related to human subjects protection.",ok
Secondary data analysis,primary\llama-DMPs\Secondary data analysis-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","The primary factor affecting subsequent access, distribution, or reuse of our scientific data is the protection of human research participants' privacy and confidentiality. All participants have provided consent for broad data sharing, but certain identifying information will be removed or de-identified to protect their privacy.",ok
Secondary data analysis,primary\llama-DMPs\Secondary data analysis-llama3.3.md,2. **Whether access to scientific data will be controlled:**,Access to the scientific data will not be controlled beyond the standard procedures and requirements of the NDA for ensuring appropriate use and protecting human subjects' data.,ok
Secondary data analysis,primary\llama-DMPs\Secondary data analysis-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","To protect the privacy, rights, and confidentiality of human research participants, all shared data will be de-identified. Additionally, we will obtain Certificates of Confidentiality from the NIH to further safeguard against disclosure of sensitive information.",ok
Secondary data analysis,primary\llama-DMPs\Secondary data analysis-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be monitored and managed by our institution's research administration office, specifically through the roles of the Principal Investigator and a designated data manager. Oversight will include regular checks (at least quarterly) to ensure that data are being properly curated, shared in accordance with the plan, and that all necessary documentation and metadata are up-to-date and accessible.",ok
Human clinical and genomics data,primary\llama-DMPs\Human clinical and genomics data-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"This study expects to generate a significant amount of clinical and genomic data from approximately 1000 participants. Clinical data will include demographical information, insurance status, medical history, medications, lab tests (both from clinical sites and central laboratories), physical exams data, and other relevant clinical data collected at varying frequencies over up to 12 months. Genomic data will comprise individual-level data including Whole Exome Sequencing (WES), shallow Whole Genome Sequencing (WGS), and DNA methylation arrays (EPIC), totaling around 10 TB of genomic data.",ok
Human clinical and genomics data,primary\llama-DMPs\Human clinical and genomics data-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All clinical and genomic data collected during this study will be preserved and shared. The rationale is to contribute to the broader scientific community's understanding of the relationship between genotype and phenotype in the context of this study, facilitating future research, replication studies, and meta-analyses that could lead to significant advancements in healthcare and treatments.",ok
Human clinical and genomics data,primary\llama-DMPs\Human clinical and genomics data-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","Metadata will include participant identifiers, collection dates, types of assays performed, and technical details about genomic analyses (e.g., sequencing depth, coverage). Other relevant data will encompass study protocols, case report forms used for clinical data collection, and detailed descriptions of bioinformatic pipelines used for genomic data analysis. Associated documentation will also include consent forms that explicitly allow for broad data sharing.",ok
Human clinical and genomics data,primary\llama-DMPs\Human clinical and genomics data-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools, software, and code are needed to access or manipulate shared scientific data. For genomic data analysis, this may include bioinformatic pipelines such as BWA for alignment, GATK for variant calling, and R packages for statistical analysis. Access to these tools can be facilitated through open-source repositories like GitHub or Bioconductor, where applicable.",ok
Human clinical and genomics data,primary\llama-DMPs\Human clinical and genomics data-llama3.3.md,### Element 3: Standards:,"Common data standards applied will include those recommended by the NIH for genomic data (e.g., VCF for variant calls) and clinical data (e.g., CDISC standards for clinical trials data). Metadata standards such as ISA-Tab will be used to describe experimental conditions, sample characteristics, and assay details. These standards enable interoperability of datasets and resources, facilitating their integration and analysis across different studies.",ok
Human clinical and genomics data,primary\llama-DMPs\Human clinical and genomics data-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,"The scientific data and metadata arising from this project will be archived in the NICHD DASH repository as well as other NIH-approved repositories for genomic and clinical data (e.g., dbGaP for genomic data, ClinicalTrials.gov for clinical trial data).",ok
Human clinical and genomics data,primary\llama-DMPs\Human clinical and genomics data-llama3.3.md,2. **How scientific data will be findable and identifiable:**,Scientific data will be made findable and identifiable through the use of persistent unique identifiers such as DOI numbers or accession numbers provided by the repositories where the data are archived.,ok
Human clinical and genomics data,primary\llama-DMPs\Human clinical and genomics data-llama3.3.md,3. **When and how long the scientific data will be made available:**,"The scientific data will be made available no later than the time of publication of the main findings from the study or at the end of the performance period, whichever comes first. The data will remain available for at least 10 years after the study's completion to allow for extended research and validation studies.",ok
Human clinical and genomics data,primary\llama-DMPs\Human clinical and genomics data-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","Given that all participants are consented for broad data sharing, limitations on access, distribution, or reuse will primarily pertain to protecting participant privacy and confidentiality. However, no additional factors beyond standard protections for human subjects research are anticipated.",ok
Human clinical and genomics data,primary\llama-DMPs\Human clinical and genomics data-llama3.3.md,2. **Whether access to scientific data will be controlled:**,"Access to certain aspects of the genomic data may be controlled through mechanisms like dbGaP, which requires users to apply for access and agree to terms of use that protect participant confidentiality.",ok
Human clinical and genomics data,primary\llama-DMPs\Human clinical and genomics data-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","To protect participant privacy, rights, and confidentiality, all shared data will be de-identified according to HIPAA guidelines. The study has also obtained a Certificate of Confidentiality from the NIH to further safeguard against disclosure of sensitive information.",ok
Human clinical and genomics data,primary\llama-DMPs\Human clinical and genomics data-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be monitored and managed by the study's Principal Investigator in collaboration with the institution's data management and compliance offices. Regular oversight meetings (at least quarterly) will ensure that data collection, storage, sharing, and protection practices adhere to the plan and all relevant regulations and guidelines.",ok
Gene expression analysis data from non-human model organism (zebrafish),primary\llama-DMPs\Gene expression analysis data from non-human model organism (zebrafish)-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"The proposed project is expected to generate several types of scientific data from approximately 200 zebrafish embryos (100 wild types and 100 phox2bb:mNeonGreen reporter transgenic fish embryos). The primary data types include:
   - *In situ hybridization images (.png, .jpeg files) for genes of interest using digoxigenin-labeled antisense RNA probes.
   - *Transcriptional profiling data from NeonGreen labeled cells through bulk RNA-seq analysis, single cell clustering and expression analysis, and/or single cell RNA-seq (scRNA-seq).
   - Detailed cis-regulatory and open chromatin analysis data from single cell ATAC-seq.
   - Raw data will be collected as fastq files, which will then be transformed into matrices and bed files using standard workflows for bulk RNA-seq, scRNA-seq, and ATAC-seq analyses.",ok
Gene expression analysis data from non-human model organism (zebrafish),primary\llama-DMPs\Gene expression analysis data from non-human model organism (zebrafish)-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All raw and processed data from in situ hybridization, bulk RNA-seq, scRNA-seq, and ATAC-seq experiments will be preserved and shared. The rationale is to facilitate transparency, reproducibility, and further research by making these datasets available to the scientific community. Sharing these data aligns with the principles of open science and can accelerate discoveries related to gene expression and regulatory mechanisms in zebrafish models.",ok
Gene expression analysis data from non-human model organism (zebrafish),primary\llama-DMPs\Gene expression analysis data from non-human model organism (zebrafish)-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","To facilitate interpretation of the scientific data, the following will be made accessible:
   - Metadata: Sample information (e.g., embryo type, experimental conditions), sequencing parameters, and analysis pipeline details.
   - Other relevant data: Gene expression levels, differential gene expression analyses, and chromatin accessibility data.
   - Associated documentation: Study protocols, data collection instruments, and detailed methods for each experiment.",ok
Gene expression analysis data from non-human model organism (zebrafish),primary\llama-DMPs\Gene expression analysis data from non-human model organism (zebrafish)-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools, software, and/or code are needed to access or manipulate shared scientific data. These include:
- Bioinformatics pipelines for RNA-seq and ATAC-seq data analysis (e.g., HISAT2, FeatureCounts, DESeq2).
- Single-cell analysis tools (e.g., Seurat, Scanpy).*
- Genomic browsers (e.g., UCSC Genome Browser, IGV) for visualizing chromatin accessibility and gene expression data.
These tools are widely used in the field and can be accessed through their respective websites or repositories (e.g., GitHub, Bioconductor).",ok
Gene expression analysis data from non-human model organism (zebrafish),primary\llama-DMPs\Gene expression analysis data from non-human model organism (zebrafish)-llama3.3.md,### Element 3: Standards:,"Common data standards will be applied to the scientific data and associated metadata to enable interoperability of datasets and resources. Specifically:
- FASTQ files for raw sequencing data, adhering to the FASTQ format standard.
- BED and bigWig files for genome-wide data (e.g., ATAC-seq peaks, gene expression levels), following the ENCODE data standards.
- Metadata will be described using standardized ontologies (e.g., EFO, DOID) where applicable.
These standards are chosen because they are widely adopted in the genomics and transcriptomics communities, facilitating data integration and comparison across studies.",ok
Gene expression analysis data from non-human model organism (zebrafish),primary\llama-DMPs\Gene expression analysis data from non-human model organism (zebrafish)-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,"The scientific data and metadata arising from this project will be archived in the Gene Expression Omnibus (GEO) repository and/or the NCBI Sequence Read Archive (SRA), which are appropriate for genomics and transcriptomics data.",ok
Gene expression analysis data from non-human model organism (zebrafish),primary\llama-DMPs\Gene expression analysis data from non-human model organism (zebrafish)-llama3.3.md,2. **How scientific data will be findable and identifiable:**,"Data will be made findable and identifiable through the assignment of unique identifiers (e.g., GEO accession numbers, SRA run accessions) and standard indexing tools like PubMed and Google Scholar.",ok
Gene expression analysis data from non-human model organism (zebrafish),primary\llama-DMPs\Gene expression analysis data from non-human model organism (zebrafish)-llama3.3.md,3. **When and how long the scientific data will be made available:**,"The scientific data will be made available to other users no later than the time of publication of the main findings or at the end of the performance period, whichever comes first. The data will remain accessible for a minimum of 10 years after the project's completion, adhering to NIH guidelines and repository policies.",ok
Gene expression analysis data from non-human model organism (zebrafish),primary\llama-DMPs\Gene expression analysis data from non-human model organism (zebrafish)-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","Given that this project involves zebrafish embryos and not human subjects, there are no limitations related to informed consent, privacy, or confidentiality protections. However, any reuse of the data should properly cite the original publication and adhere to the terms of use specified by the repositories where the data are archived.",ok
Gene expression analysis data from non-human model organism (zebrafish),primary\llama-DMPs\Gene expression analysis data from non-human model organism (zebrafish)-llama3.3.md,2. **Whether access to scientific data will be controlled:**,"Access to the scientific data will not be controlled beyond what is standard for public repositories like GEO or SRA. Data will be available for download without restrictions, other than those imposed by the repository's terms of service.",ok
Gene expression analysis data from non-human model organism (zebrafish),primary\llama-DMPs\Gene expression analysis data from non-human model organism (zebrafish)-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","This project does not involve human subjects; therefore, protections for human research participant privacy, rights, and confidentiality are not applicable.",ok
Gene expression analysis data from non-human model organism (zebrafish),primary\llama-DMPs\Gene expression analysis data from non-human model organism (zebrafish)-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be monitored and managed by the Principal Investigator (PI) in collaboration with the institution's Research Data Management Office. Oversight activities include regular checks on data deposition into designated repositories, ensuring metadata completeness, and verifying that shared data are properly cited in publications. The PI and the data management team will meet bi-annually to review progress and address any issues related to data sharing and management.",ok
Human survey data,primary\llama-DMPs\Human survey data-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"The study anticipates generating a significant amount of data from survey interviews with 2,500 children aged 8-17 years and 1,500 primary caregivers, as well as child time diaries. This will include raw interview data, recoded data for missing values or top coding, scale composites, and individual-level links to detailed school data from the National Center for Education Statistics (NCES) and contextual data based on geocodes for family residences.",ok
Human survey data,primary\llama-DMPs\Human survey data-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All collected data, including survey responses, time diaries, recoded datasets, scale composites, and linked school and contextual data, will be preserved and shared. The rationale is to provide a comprehensive, nationally representative dataset on children aged 8-17 and their primary caregivers, facilitating future research on child development, education outcomes, and health.",ok
Human survey data,primary\llama-DMPs\Human survey data-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","Associated metadata will include participant demographics, survey and diary collection protocols, data cleaning and recoding procedures, and documentation of how scale composites were constructed. Study protocols, consent forms, and data collection instruments will also be made accessible to facilitate interpretation and potential replication of the study findings.",ok
Human survey data,primary\llama-DMPs\Human survey data-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools and software needed for data analysis include statistical packages like R or SPSS for survey data analysis and GIS software for geocode-based contextual data analysis. Specific code used for recoding, constructing scale composites, and linking datasets will be documented and shared through repositories like GitHub to ensure transparency and reproducibility.",ok
Human survey data,primary\llama-DMPs\Human survey data-llama3.3.md,### Element 3: Standards:,"The project will apply common data standards for demographic, educational, and health data to enable interoperability with other national datasets. Specifically, data will be formatted according to the Data Documentation Initiative (DDI) standards for social science data, ensuring that metadata is comprehensive and facilitates understanding and reuse of the dataset. For geospatial data, standards from the Open Geospatial Consortium (OGC) will be used.",ok
Human survey data,primary\llama-DMPs\Human survey data-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,"The scientific data and associated metadata will be archived in a trusted repository such as the ICPSR (Inter-university Consortium for Political and Social Research) or the National Archive of Child Health and Human Development, ensuring long-term preservation and accessibility.",ok
Human survey data,primary\llama-DMPs\Human survey data-llama3.3.md,2. **How scientific data will be findable and identifiable:**,"Data will be made findable through DOIs (Digital Object Identifiers) assigned by the repository and indexed in major search engines and academic databases, facilitating easy discovery and access.",ok
Human survey data,primary\llama-DMPs\Human survey data-llama3.3.md,3. **When and how long the scientific data will be made available:**,"Scientific data will be made available no later than the time of publication of the main findings or within 12 months of the project's completion, whichever comes first. The data will remain accessible for at least 10 years after the initial release to allow for extensive use by the research community.",ok
Human survey data,primary\llama-DMPs\Human survey data-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","Given that all participants are consented for broad data sharing, limitations on access will primarily be related to protecting participant privacy and confidentiality, adhering to IRB-approved protocols, and complying with federal regulations regarding human subjects research.",ok
Human survey data,primary\llama-DMPs\Human survey data-llama3.3.md,2. **Whether access to scientific data will be controlled:**,Access to identifiable data will be controlled through a data use agreement that requires users to agree not to attempt to identify participants or breach confidentiality. De-identified data will be openly accessible without restriction.,ok
Human survey data,primary\llama-DMPs\Human survey data-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","To protect participant privacy, all shared datasets will be de-identified, removing direct identifiers and applying statistical methods to prevent re-identification. Certificates of Confidentiality will be obtained from the NIH to further safeguard sensitive information.",ok
Human survey data,primary\llama-DMPs\Human survey data-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be monitored by the project's Principal Investigator (PI) in collaboration with the institution's data management office. Regular oversight meetings will occur every six months to review data collection progress, ensure adherence to sharing timelines, and address any issues related to data privacy or accessibility. The PI will also work closely with the IRB to ensure that all data sharing practices comply with ethical standards and federal regulations.",ok
Clinical Data from Human Research Participants,primary\llama-DMPs\Clinical Data from Human Research Participants-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"This study aims to collect renal dialysis data from multiple clinics, focusing on demographic information, laboratory results, clinical observations, and clinical disposition from 250 affected participants and 250 matched healthy controls. The estimated amount of data includes but is not limited to:  
     - Demographic data (age, sex, ethnicity, etc.) for 500 participants.  
     - Laboratory results (e.g., blood chemistry, hematology) which could generate up to 100 different metrics per participant visit, with an average of 10 visits per participant over the study period, totaling approximately 50,000 laboratory result data points.  
     - Clinical observations and clinical disposition data, which may include notes, diagnoses, treatments, and outcomes, potentially generating a substantial amount of textual and categorical data.",ok
Clinical Data from Human Research Participants,primary\llama-DMPs\Clinical Data from Human Research Participants-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All collected data (demographic, laboratory results, clinical observations, and clinical disposition) will be preserved and shared because it is crucial for understanding renal dialysis outcomes, improving patient care, and facilitating future research in this area. Sharing these data will enable other researchers to replicate findings, combine datasets for more powerful analyses, and explore new hypotheses that could lead to better health outcomes for patients undergoing renal dialysis.",ok
Clinical Data from Human Research Participants,primary\llama-DMPs\Clinical Data from Human Research Participants-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","To facilitate interpretation of the scientific data, the following metadata and documentation will be made accessible:  
     - Study protocols outlining the methodology for data collection and analysis.  
     - Data collection instruments (e.g., questionnaires, case report forms).  
     - Data dictionaries explaining variable names, formats, and descriptions.  
     - Documentation of any data transformations or quality control processes applied to the data.",ok
Clinical Data from Human Research Participants,primary\llama-DMPs\Clinical Data from Human Research Participants-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools and software needed to access or manipulate shared scientific data include statistical analysis packages (e.g., R, Python libraries like Pandas and NumPy) for data manipulation and analysis, and potentially data visualization tools (e.g., Tableau, Power BI) for exploratory data analysis. These tools are widely available and accessible through academic licenses or open-source repositories.",ok
Clinical Data from Human Research Participants,primary\llama-DMPs\Clinical Data from Human Research Participants-llama3.3.md,### Element 3: Standards:,"To enable interoperability of datasets and resources, common data standards will be applied to the scientific data and associated metadata. Specifically, the study will adhere to the Clinical Data Interchange Standards Consortium (CDISC) standards for clinical trials data, including the Study Data Tabulation Model (SDTM) for organizing and formatting data. These standards are widely recognized in the field of clinical research and facilitate the sharing and comparison of data across studies.",ok
Clinical Data from Human Research Participants,primary\llama-DMPs\Clinical Data from Human Research Participants-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,"The scientific data and metadata arising from this project will be archived in the National Institutes of Health (NIH)’s National Library of Medicine (NLM) repository, specifically through the Database of Genotypes and Phenotypes (dbGaP) for genomic data or other appropriate NIH-supported repositories for non-genomic data.",ok
Clinical Data from Human Research Participants,primary\llama-DMPs\Clinical Data from Human Research Participants-llama3.3.md,2. **How scientific data will be findable and identifiable:**,"The scientific data will be made findable and identifiable through the assignment of a persistent unique identifier (e.g., DOI - Digital Object Identifier) and indexing in standard databases relevant to the field of renal dialysis research, ensuring that the data can be easily located and accessed by other researchers.",ok
Clinical Data from Human Research Participants,primary\llama-DMPs\Clinical Data from Human Research Participants-llama3.3.md,3. **When and how long the scientific data will be made available:**,"The scientific data will be made available no later than the time of publication of the main findings or within 12 months of the primary collection period ending, whichever comes first. The data will remain accessible for a minimum of 10 years after the study’s completion to allow for extended research and analysis opportunities.",ok
Clinical Data from Human Research Participants,primary\llama-DMPs\Clinical Data from Human Research Participants-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","While maximizing data sharing is a priority, considerations related to participant privacy and confidentiality will be taken into account. Data will be de-identified to protect participants’ identities, in compliance with the Health Insurance Portability and Accountability Act (HIPAA) regulations. Any limitations on data sharing due to these protections will be clearly documented and justified.",ok
Clinical Data from Human Research Participants,primary\llama-DMPs\Clinical Data from Human Research Participants-llama3.3.md,2. **Whether access to scientific data will be controlled:**,"Access to the scientific data will not be controlled beyond what is required for protecting human subjects’ confidentiality and adhering to NIH policies on data sharing. Data will be made available through a publicly accessible repository, with no requirement for approval or permission beyond standard repository usage agreements.",ok
Clinical Data from Human Research Participants,primary\llama-DMPs\Clinical Data from Human Research Participants-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","To protect the privacy, rights, and confidentiality of human research participants, all shared data will be de-identified using standardized methods (e.g., removal of direct identifiers, use of coded identifiers). Additionally, a Certificate of Confidentiality will be obtained from the NIH to further safeguard against disclosure of sensitive information. Participants will provide broad consent for data sharing as part of their informed consent process.",ok
Clinical Data from Human Research Participants,primary\llama-DMPs\Clinical Data from Human Research Participants-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be monitored and managed by the study’s Principal Investigator (PI) in collaboration with the institution’s Research Integrity Office and Information Technology department. Regular reviews (at least annually) will be conducted to ensure adherence to the plan, including verification that data are properly archived, shared according to the timelines outlined, and that any issues related to data privacy or access are promptly addressed. The PI will be responsible for reporting any deviations from the plan to the NIH as required.",ok
Human genomic data,primary\llama-DMPs\Human genomic data-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"The proposed research project is anticipated to generate a substantial amount of genomic, transcriptomic, and clinical data. The dataset will include array-derived genotype data from approximately 1,000 human participants (500 cases and 500 controls), 30x whole-genome sequencing (WGS) data for the same cohort, RNA sequencing (RNA-seq) data to analyze gene expression profiles, Hi-C WGS data for 3D genomic structure information, phenotypic and clinical data from institutional electronic health records (EHRs), and demographic data including age, sex, ethnicity, among others. The estimated volume of data will be significant, with each type of sequencing data contributing hundreds of gigabytes per participant.",ok
Human genomic data,primary\llama-DMPs\Human genomic data-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All types of scientific data generated in this project (genomic, transcriptomic, clinical, and demographic) will be preserved and shared. The rationale behind sharing these data is to contribute meaningfully to the scientific community by providing comprehensive insights into genomic structure, gene expression, and their correlations with clinical outcomes. This data sharing will facilitate further research, validation of findings, and potential discovery of novel therapeutic targets or biomarkers.",ok
Human genomic data,primary\llama-DMPs\Human genomic data-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","To facilitate the interpretation and reuse of shared scientific data, metadata such as sample identifiers, sequencing library preparation methods, and data processing pipelines will be made accessible. Other relevant data include participant consent forms, study protocols, and detailed descriptions of clinical and demographic variables extracted from EHRs. Associated documentation, like data collection instruments and analytical software versions, will also be provided.",ok
Human genomic data,primary\llama-DMPs\Human genomic data-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools and software are required to access and manipulate the shared scientific data. Key tools include but are not limited to Illumina sequencing analysis software for primary data processing, Bioconductor packages in R for RNA-seq analysis, and HiC-Pro for Hi-C data processing. Access to these tools can be obtained through their respective official websites or repositories (e.g., CRAN for R packages).",ok
Human genomic data,primary\llama-DMPs\Human genomic data-llama3.3.md,### Element 3: Standards:,"To ensure interoperability of datasets and resources, common data standards will be applied. For genomic and transcriptomic data, the FASTQ and BAM formats will be used. Clinical and demographic data will adhere to standardized vocabulary and coding systems such as SNOMED-CT and ICD-10 for clinical terms and ethnicity/race categorizations based on NIH guidelines. Metadata will follow the MINSEQE guidelines for sequencing experiments. If applicable, adherence to emerging standards in 3D genomic structure analysis (e.g., Hi-C data) will be considered.",ok
Human genomic data,primary\llama-DMPs\Human genomic data-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,"The scientific data and associated metadata from this project will be archived in the Database of Genotypes and Phenotypes (dbGaP), a repository that allows for controlled access to genomic data from human participants, ensuring compliance with NIH policies on sharing human data.",ok
Human genomic data,primary\llama-DMPs\Human genomic data-llama3.3.md,2. **How scientific data will be findable and identifiable:**,Data will be made findable through the use of persistent unique identifiers such as dbGaP study accession numbers and DOI (Digital Object Identifier) links for associated publications. Standard indexing tools like PubMed and Google Dataset Search will also facilitate discoverability.,ok
Human genomic data,primary\llama-DMPs\Human genomic data-llama3.3.md,3. **When and how long the scientific data will be made available:**,"The scientific data will be made available no later than the time of publication of the main findings or at the end of the performance period, whichever comes first. Data will remain accessible for a minimum of 10 years after the project's completion to allow for extensive use by the research community.",ok
Human genomic data,primary\llama-DMPs\Human genomic data-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","While maximizing data sharing is a priority, factors such as informed consent limitations and protecting participant privacy and confidentiality will be considered. Given that all participants are consented for broad data sharing, the primary limitation will be ensuring de-identification of clinical and demographic data to prevent re-identification risks.",ok
Human genomic data,primary\llama-DMPs\Human genomic data-llama3.3.md,2. **Whether access to scientific data will be controlled:**,"Access to certain datasets, particularly those containing potentially identifiable human information, will be controlled through dbGaP's authorization process, requiring users to register and agree to terms of use that protect participant confidentiality.",ok
Human genomic data,primary\llama-DMPs\Human genomic data-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","To protect the privacy, rights, and confidentiality of human research participants, all shared data will undergo rigorous de-identification processes, removing direct identifiers and applying methods to minimize re-identification risks (e.g., aggregating certain variables). Furthermore, a Certificate of Confidentiality will be obtained from NIH to provide additional legal protections against compelled disclosure of identifiable information.",ok
Human genomic data,primary\llama-DMPs\Human genomic data-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be monitored and managed by the institution's data management oversight committee, which includes representatives from the research team, the Office of Research Compliance, and the Library's Data Services. Regular reviews (at least bi-annually) will ensure adherence to the plan, address any emerging issues or changes in policies, and confirm that all shared data are properly documented and accessible according to the stated timelines.",ok
Technology development,primary\llama-DMPs\Technology development-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"The proposed project is anticipated to generate several types of high-throughput sequencing data from 20 human cell lines obtained from BIOBANK X, utilizing technologies developed by Small Business X Technology. The primary datasets include:
   - Nanopore sequence data: Long-read sequencing data will be produced for all 20 human cell lines using Oxford Nanopore technology. This is expected to yield approximately 100 GB of data per cell line, enabling comprehensive structural variant detection and improved genome assembly.
   - 30x whole-genome sequencing (WGS) data: High-coverage short-read sequencing will be performed on the same 20 cell lines to generate detailed genomic variant data, anticipating about 500 GB of data per cell line.
   - RNA sequencing (RNA-seq) data: Transcriptomic profiling will be conducted on all cell lines, aiming for approximately 50 GB of data per cell line, to capture gene expression dynamics and support integrative omics analyses.",ok
Technology development,primary\llama-DMPs\Technology development-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All generated sequencing data (Nanopore, WGS, and RNA-seq) along with associated metadata will be preserved and shared. The rationale behind this decision is to facilitate open access to comprehensive genomic and transcriptomic information, promoting collaborative research, validation of findings, and advancement in the field of genomics and human health.",ok
Technology development,primary\llama-DMPs\Technology development-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","To facilitate interpretation and reuse of the scientific data, the following will be made accessible:
   - Sample metadata: Information on cell line origin, processing protocols, and sequencing parameters.
   - Study protocols: Detailed descriptions of experimental design, methods used for data generation, and quality control measures.
   - Data collection instruments: Any software or tools utilized in data acquisition and analysis.",ok
Technology development,primary\llama-DMPs\Technology development-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools and software are necessary for accessing and manipulating the shared scientific data. Specifically, users will need access to bioinformatic analysis pipelines capable of handling high-throughput sequencing data, such as those utilizing Python, R, or specialized genomic analysis software like SAMtools, BWA, and GATK. These tools can be accessed through various open-source repositories and bioinformatics platforms.",ok
Technology development,primary\llama-DMPs\Technology development-llama3.3.md,### Element 3: Standards:,"To ensure interoperability and facilitate the integration of datasets, the project will adhere to established data standards for genomic and transcriptomic data, including but not limited to:
- FASTQ and SAM/BAM formats for sequencing data.
- VCF format for variant calling data.
- BED and GTF formats for genomic feature data.
These standards are widely adopted in the genomics community, enabling efficient data exchange and analysis across different platforms.",ok
Technology development,primary\llama-DMPs\Technology development-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,"The scientific data and associated metadata arising from this project will be archived in the National Center for Biotechnology Information (NCBI) database, specifically through repositories like the Sequence Read Archive (SRA) for raw sequencing data and the Gene Expression Omnibus (GEO) for processed RNA-seq data.",ok
Technology development,primary\llama-DMPs\Technology development-llama3.3.md,2. **How scientific data will be findable and identifiable:**,"Each dataset will be assigned a unique identifier (e.g., SRA accession numbers, GEO series IDs), facilitating easy location and access through standard indexing tools and search interfaces provided by the repositories.",ok
Technology development,primary\llama-DMPs\Technology development-llama3.3.md,3. **When and how long the scientific data will be made available:**,"The scientific data will be made available to other users no later than the time of publication of the main findings or at the end of the performance period, whichever comes first. The data are expected to remain accessible indefinitely, as per the policies of the chosen repositories, to support long-term research and validation.",ok
Technology development,primary\llama-DMPs\Technology development-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","Given that all research participants will provide consent for broad data sharing, there are no anticipated limitations on access, distribution, or reuse related to informed consent. However, privacy and confidentiality protections will be ensured through de-identification of human subjects’ data and adherence to relevant regulations like the Health Insurance Portability and Accountability Act (HIPAA).",ok
Technology development,primary\llama-DMPs\Technology development-llama3.3.md,2. **Whether access to scientific data will be controlled:**,"Access to the scientific data will not be controlled beyond the standard access controls implemented by the repositories where the data are archived, ensuring open access to the research community.",ok
Technology development,primary\llama-DMPs\Technology development-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","To protect the privacy, rights, and confidentiality of human research participants, all shared data will be de-identified. Additionally, the project will comply with all relevant federal regulations and guidelines concerning human subjects research, including obtaining a Certificate of Confidentiality if necessary, to safeguard sensitive information.",ok
Technology development,primary\llama-DMPs\Technology development-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be monitored and managed by the Principal Investigator (PI) in collaboration with the institution’s Research Data Management Office. Regular oversight will occur through quarterly project meetings where data generation, sharing progress, and any challenges encountered will be discussed. The PI and designated data managers will ensure that all data sharing activities adhere to the outlined plan, relevant policies, and ethical standards.",ok
Basic Research from a Non-Human Source Example,primary\llama-DMPs\Basic Research from a Non-Human Source Example-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"This project aims to generate three primary datasets from mouse models of nonalcoholic steatohepatitis (NASH)-driven hepatocellular carcinoma (HCC). The datasets will include:
     - Clinical and phenotypic data: This will encompass a wide range of characteristics such as animal sex, body weight, specific organ weights, age, developmental stage, tissue profiled, and disease outcome for up to 50 mice.
     - RNA sequencing datasets: These will contain normalized transcript and gene-level expression counts along with quality control metrics like total reads, clipped reads, sequencing platform, and other relevant metrics that may emerge during the project.
     - Microscopic imaging data: This will comprise light and confocal microscopy images of formaldehyde-fixed paraffin-embedded tissue slices.",ok
Basic Research from a Non-Human Source Example,primary\llama-DMPs\Basic Research from a Non-Human Source Example-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All three datasets (clinical/phenotypic, RNA sequencing, and microscopic imaging) will be preserved and shared. The rationale behind sharing these comprehensive datasets is to facilitate a deeper understanding of NASH-driven HCC, promote collaboration among researchers, and accelerate the discovery of therapeutic targets. Sharing these data aligns with the principles of transparency, reproducibility, and advancing biomedical research.",ok
Basic Research from a Non-Human Source Example,primary\llama-DMPs\Basic Research from a Non-Human Source Example-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","To ensure the datasets are interpretable and usable by others, the following metadata and documentation will be made accessible:
     - Study protocols
     - Data collection instruments
     - Detailed methodologies for RNA sequencing and microscopic imaging
     - Animal housing and care conditions
     - Experimental design documents
     - Data processing and analysis pipelines",ok
Basic Research from a Non-Human Source Example,primary\llama-DMPs\Basic Research from a Non-Human Source Example-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools and software will be required to access or manipulate the shared scientific data. Specifically, for RNA sequencing data, tools like DESeq2, edgeR, or similar packages in R or Python will be necessary for differential gene expression analysis. For microscopic imaging data, software such as ImageJ or proprietary confocal microscopy analysis tools may be needed. These tools are widely available in the research community and can be accessed through various channels, including open-source repositories and commercial vendors.",ok
Basic Research from a Non-Human Source Example,primary\llama-DMPs\Basic Research from a Non-Human Source Example-llama3.3.md,### Element 3: Standards:,"To ensure interoperability of datasets and resources, common data standards will be applied. For RNA sequencing data, compliance with the FAIR (Findable, Accessible, Interoperable, Reusable) principles will be achieved by using standardized formats like BAM for aligned reads and CSV or TSV for gene expression counts. Microscopic images will be stored in standard formats such as TIFF or JPEG2000. Clinical and phenotypic data will adhere to metadata standards recommended by the National Center for Biotechnology Information (NCBI) or similar authoritative bodies. If applicable, the lack of consensus standards in certain areas will be addressed through the use of community-accepted best practices.",ok
Basic Research from a Non-Human Source Example,primary\llama-DMPs\Basic Research from a Non-Human Source Example-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,"The datasets generated from this project will be archived in the [NCBI's Gene Expression Omnibus (GEO)](https://www.ncbi.nlm.nih.gov/geo/) for RNA sequencing data and in a suitable repository like [Zenodo](https://zenodo.org/) or [Dryad](https://datadryad.org/stash) for clinical/phenotypic data and microscopic imaging, ensuring long-term preservation and accessibility.",ok
Basic Research from a Non-Human Source Example,primary\llama-DMPs\Basic Research from a Non-Human Source Example-llama3.3.md,2. **How scientific data will be findable and identifiable:**,"Each dataset will be assigned a unique and persistent identifier (e.g., DOI for Zenodo or Dryad, and GEO accession numbers for RNA sequencing data). This will enable easy location and citation of the datasets.",ok
Basic Research from a Non-Human Source Example,primary\llama-DMPs\Basic Research from a Non-Human Source Example-llama3.3.md,3. **When and how long the scientific data will be made available:**,"The scientific data will be made available no later than the time of publication of the main findings from the project or at the end of the performance period, whichever comes first. The data are expected to remain accessible for a minimum of 10 years after the project's completion to allow for long-term research utility and compliance with NIH policies.",ok
Basic Research from a Non-Human Source Example,primary\llama-DMPs\Basic Research from a Non-Human Source Example-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","Since this project involves mouse models, issues related to human subject confidentiality do not apply. However, any sharing of data will be done in accordance with the terms agreed upon with any collaborators and will respect the intellectual property rights of all parties involved.",ok
Basic Research from a Non-Human Source Example,primary\llama-DMPs\Basic Research from a Non-Human Source Example-llama3.3.md,2. **Whether access to scientific data will be controlled:**,"Access to the scientific data will be open, without the need for approval, once they are deposited into the designated public repositories.",ok
Basic Research from a Non-Human Source Example,primary\llama-DMPs\Basic Research from a Non-Human Source Example-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","As this project does not involve human subjects, protections for human research participant privacy, rights, and confidentiality are not applicable.",ok
Basic Research from a Non-Human Source Example,primary\llama-DMPs\Basic Research from a Non-Human Source Example-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with the Data Management and Sharing Plan will be overseen by the Principal Investigator (PI) in collaboration with the institution's research data management office. Regular checks (at least semi-annually) will ensure that all project data are being properly managed, shared according to the plan, and that any issues or updates are addressed promptly. The PI will also work closely with the research team to maintain data quality, security, and accessibility throughout the project's duration and beyond.",ok
Secondary Data Analysis Example,primary\llama-DMPs\Secondary Data Analysis Example-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"The project will generate a clinical dataset containing estimated kidney volumes for subjects with available imaging data within the database of Genotypes and Phenotypes (dbGaP). The dataset is expected to include approximately [number, e.g., 1,000] records, each comprising demographic information, clinical variables, and calculated kidney volume measurements. The total size of the dataset is anticipated to be around [size, e.g., 100 MB].",ok
Secondary Data Analysis Example,primary\llama-DMPs\Secondary Data Analysis Example-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All generated clinical datasets containing estimated kidney volumes will be preserved and shared. The rationale for sharing this data is to facilitate further research into kidney health and disease, potentially leading to better understanding and management of kidney conditions. Sharing these data aligns with the principles of transparency, reproducibility, and collaboration in scientific research.",ok
Secondary Data Analysis Example,primary\llama-DMPs\Secondary Data Analysis Example-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","Associated metadata will include variable descriptions, data collection protocols, and imaging analysis methodologies. Other relevant data may comprise quality control measures and validation studies for the kidney volume estimation algorithm. Documentation will also include study protocols, data dictionaries, and any software or coding scripts used in data processing and analysis.",ok
Secondary Data Analysis Example,primary\llama-DMPs\Secondary Data Analysis Example-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools and software needed to access or manipulate shared scientific data include magnetic resonance imaging (MRI) analysis software packages such as [package name, e.g., ITK-SNAP] for image segmentation and volume calculation. These tools can be accessed through their respective websites or academic licensing agreements.",ok
Secondary Data Analysis Example,primary\llama-DMPs\Secondary Data Analysis Example-llama3.3.md,### Element 3: Standards:,"The project will apply common data standards to ensure interoperability of datasets and resources. Specifically, the clinical dataset will adhere to the [standard name, e.g., HL7 FHIR] standard for electronic health records and the [standard name, e.g., DICOM] standard for medical imaging data. These standards will facilitate data sharing and integration across different research platforms and studies.",ok
Secondary Data Analysis Example,primary\llama-DMPs\Secondary Data Analysis Example-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,"The clinical dataset and associated metadata will be archived in the National Institutes of Health (NIH)’s database of Genotypes and Phenotypes (dbGaP), ensuring compliance with NIH policies on data sharing.",ok
Secondary Data Analysis Example,primary\llama-DMPs\Secondary Data Analysis Example-llama3.3.md,2. **How scientific data will be findable and identifiable:**,"Data will be made findable through a persistent unique identifier, such as a DOI (Digital Object Identifier), and indexed in the dbGaP catalog using standardized keywords and descriptors related to kidney volume analysis and MRI imaging.",ok
Secondary Data Analysis Example,primary\llama-DMPs\Secondary Data Analysis Example-llama3.3.md,3. **When and how long the scientific data will be made available:**,"The dataset will be made available no later than the time of publication of the primary results or at the end of the performance period, whichever comes first. The data will remain accessible for a minimum of 10 years following the completion of the project to allow for extended research and validation studies.",ok
Secondary Data Analysis Example,primary\llama-DMPs\Secondary Data Analysis Example-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","Given that all participants are consented for broad data sharing, there are no anticipated limitations on access, distribution, or reuse beyond standard protections for privacy and confidentiality. However, any use of the data must comply with the terms of use specified by dbGaP and respect the rights and privacy of the research participants.",ok
Secondary Data Analysis Example,primary\llama-DMPs\Secondary Data Analysis Example-llama3.3.md,2. **Whether access to scientific data will be controlled:**,"Access to the dataset will be controlled through the dbGaP authorized access mechanism, requiring users to register and agree to the terms of use before downloading the data.",ok
Secondary Data Analysis Example,primary\llama-DMPs\Secondary Data Analysis Example-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","To protect participant privacy, rights, and confidentiality, all shared data will be de-identified in accordance with the Health Insurance Portability and Accountability Act (HIPAA) guidelines. Furthermore, the project will obtain a Certificate of Confidentiality from the NIH to provide additional legal protection against compelled disclosure of identifiable research information.",ok
Secondary Data Analysis Example,primary\llama-DMPs\Secondary Data Analysis Example-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be monitored and managed by the Principal Investigator (PI), in collaboration with the institution’s research data management office. Regular oversight meetings will be conducted every six months to review data sharing progress, address any issues related to data access or use, and ensure that all shared data are properly documented and de-identified. The PI will also be responsible for reporting any updates or changes to the data sharing plan to the NIH as required.",ok
Survey and Interview Example,primary\llama-DMPs\Survey and Interview Example-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"This study aims to collect quantitative and qualitative survey data from 3,000 U.S. adults, including 40-50 fixed-scale and open-ended text items. Additionally, it will conduct digitally recorded semi-structured interviews with patients (n=40), healthcare providers (n=40), and industry professionals (n=20). The estimated amount of scientific data generated includes raw and recoded survey data, deidentified interview transcripts, codebooks, and coding summary files.",ok
Survey and Interview Example,primary\llama-DMPs\Survey and Interview Example-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All collected data, including survey responses and interview transcripts, will be preserved and shared to facilitate future research, maximize the utility of the data, and enhance reproducibility. The rationale is to contribute meaningfully to the scientific community by making comprehensive datasets available for secondary analyses, thus promoting further investigations into the topics studied.",ok
Survey and Interview Example,primary\llama-DMPs\Survey and Interview Example-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","Metadata will include participant demographics, survey and interview protocols, data collection instruments (e.g., questionnaires), codebooks for qualitative data analysis, and detailed descriptions of recoding processes for quantitative data. Associated documentation will comprise study protocols, informed consent forms, and data management plans to ensure transparency and facilitate the interpretation of shared scientific data.",ok
Survey and Interview Example,primary\llama-DMPs\Survey and Interview Example-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools and software needed for data analysis include statistical packages (e.g., R, SPSS) for quantitative data and qualitative analysis software (e.g., NVivo, Atlas.ti) for coding and analyzing interview transcripts. These tools are widely available in academic settings or can be accessed through institutional licenses, ensuring that other researchers can manipulate and analyze the shared data.",ok
Survey and Interview Example,primary\llama-DMPs\Survey and Interview Example-llama3.3.md,### Element 3: Standards:,"Common data standards to be applied include those recommended by the NIH for human subjects research, such as the use of standardized vocabularies and ontologies (e.g., PhenX toolkit measures) for enhancing data comparability and interoperability. Data will be structured in formats compliant with FAIR principles (Findable, Accessible, Interoperable, Reusable), facilitating easy discovery and integration with other datasets.",ok
Survey and Interview Example,primary\llama-DMPs\Survey and Interview Example-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,"The scientific data and metadata arising from this project will be archived in the National Center for Biotechnology Information (NCBI) database or another NIH-approved repository that aligns with the study’s focus on genomic research and human subjects, ensuring broad accessibility and long-term preservation.",ok
Survey and Interview Example,primary\llama-DMPs\Survey and Interview Example-llama3.3.md,2. **How scientific data will be findable and identifiable:**,"Data will be made findable through the use of persistent unique identifiers (e.g., DOIs) and standard indexing tools, allowing for easy location and access by other researchers.",ok
Survey and Interview Example,primary\llama-DMPs\Survey and Interview Example-llama3.3.md,3. **When and how long the scientific data will be made available:**,"Scientific data will be made available no later than the time of publication of the main findings or at the end of the performance period, whichever comes first. Data will remain accessible for a minimum of 10 years after the project’s completion to allow for extended research and analysis opportunities.",ok
Survey and Interview Example,primary\llama-DMPs\Survey and Interview Example-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","Given that all participants will provide consent for broad data sharing, limitations on access will primarily be related to protecting participant privacy and confidentiality. Measures such as deidentification of datasets and removal of personally identifiable information will be taken to mitigate these risks.",ok
Survey and Interview Example,primary\llama-DMPs\Survey and Interview Example-llama3.3.md,2. **Whether access to scientific data will be controlled:**,"Access to the shared scientific data will not be controlled beyond what is required for protecting human subject privacy and ensuring compliance with applicable laws and regulations, such as HIPAA.",ok
Survey and Interview Example,primary\llama-DMPs\Survey and Interview Example-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","To protect participant privacy, all data will be deidentified, and open-ended text items will be reviewed for potential privacy disclosure risks and redacted as necessary. Additionally, the use of Certificates of Confidentiality will be explored to further safeguard sensitive information.",ok
Survey and Interview Example,primary\llama-DMPs\Survey and Interview Example-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be monitored and managed by the study’s Principal Investigator in conjunction with the institutional data management office. Regular checks (every six months) will ensure that data collection, storage, and sharing practices adhere to the outlined plan, facilitating timely corrections if deviations occur. Oversight responsibilities include ensuring data quality, maintaining documentation of data sharing activities, and coordinating with the repository for data archiving.",ok
Human Clinical Trial Data,primary\llama-DMPs\Human Clinical Trial Data-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"The proposed study is expected to generate a significant amount of clinical, laboratory, and imaging data from approximately 360 participants (180 mother-infant pairs) across three sites. Clinical data will include medical history, demographic information, patient characteristics, lab tests, physical exams, blood pressure measurements, fetal monitoring assessments, and pregnancy outcomes. Laboratory data will comprise results from urinalysis, analysis of angiogenic factors, uric acid, glycemia, and other research-specific tests. Imaging data will consist of 2D Doppler studies of uterine, umbilical, and middle cerebral arteries; 3D images of the fetal thigh for volume measurements; and real-time grayscale 2D clips of the fetal heart. This data will be collected at enrollment, during antepartum management, at delivery, and through infant follow-up visits at 3, 6, and 12 months of age.",ok
Human Clinical Trial Data,primary\llama-DMPs\Human Clinical Trial Data-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All clinical, laboratory, and imaging data collected throughout the study will be preserved and shared to facilitate future research into early onset preeclampsia, improve antepartum management strategies, enhance neonatal outcomes, and contribute to the understanding of maternal and fetal health. Sharing these data will enable other researchers to replicate findings, conduct meta-analyses, and explore new hypotheses that could lead to better prevention and treatment options for preeclampsia.",ok
Human Clinical Trial Data,primary\llama-DMPs\Human Clinical Trial Data-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","Associated metadata will include participant IDs, visit dates, types of measurements taken (e.g., blood pressure, lab tests), imaging protocols used, and outcomes assessed (e.g., days of maintaining pregnancy, neonatal health metrics). Other relevant data will encompass study protocols, informed consent documents, data collection instruments, and detailed descriptions of analytical methods used for laboratory and imaging assessments. These will be made accessible to ensure transparency, facilitate interpretation of the scientific data, and enable reproducibility.",ok
Human Clinical Trial Data,primary\llama-DMPs\Human Clinical Trial Data-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools and software needed to access or manipulate shared scientific data include REDCap for clinical and laboratory data management, and specific imaging analysis software (e.g., DICOM viewers for cardiac clips, proprietary software for 3D image analysis of fetal thigh volumes). Details on accessing these tools will be provided in the data sharing plan appendix.",ok
Human Clinical Trial Data,primary\llama-DMPs\Human Clinical Trial Data-llama3.3.md,### Element 3: Standards:,"Common data standards to be applied include those recommended by the National Institutes of Health (NIH) for clinical and laboratory data, such as the Clinical Data Interchange Standards Consortium (CDISC) standards for clinical trials data. For imaging data, standards will follow the Digital Imaging and Communications in Medicine (DICOM) format for medical images. These standards will enable interoperability and facilitate the combination of datasets from different studies.",ok
Human Clinical Trial Data,primary\llama-DMPs\Human Clinical Trial Data-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,"The scientific data and associated metadata arising from this project will be archived in a NIH-approved repository, such as the National Center for Biotechnology Information (NCBI) or other appropriate repositories designated by the NIH for specific data types (e.g., imaging data in the Cancer Imaging Archive).",ok
Human Clinical Trial Data,primary\llama-DMPs\Human Clinical Trial Data-llama3.3.md,2. **How scientific data will be findable and identifiable:**,"Scientific data will be made findable through the use of persistent unique identifiers, such as DOI numbers for datasets and publications, and standard indexing tools like those used by PubMed and clinical trial registries.",ok
Human Clinical Trial Data,primary\llama-DMPs\Human Clinical Trial Data-llama3.3.md,3. **When and how long the scientific data will be made available:**,"The scientific data will be made available to other users no later than the time of publication of the main findings or within one year after the completion of data collection, whichever comes first, in accordance with NIH policies. Data will be available for at least 10 years following the completion of the study to allow sufficient time for secondary analyses and replication studies.",ok
Human Clinical Trial Data,primary\llama-DMPs\Human Clinical Trial Data-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","Access to identifiable private information will be restricted due to privacy concerns, but de-identified data will be made broadly available. Limitations may also apply based on the terms of informed consent and any Certificates of Confidentiality obtained to protect participant identities.",ok
Human Clinical Trial Data,primary\llama-DMPs\Human Clinical Trial Data-llama3.3.md,2. **Whether access to scientific data will be controlled:**,"Access to certain datasets, particularly those containing identifiable or sensitive information, may require approval from a data access committee or be controlled through a data repository that reviews requests for data access.",ok
Human Clinical Trial Data,primary\llama-DMPs\Human Clinical Trial Data-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","To protect the privacy, rights, and confidentiality of human research participants, all shared data will be de-identified according to HIPAA guidelines, and participants will provide consent for broad sharing of their data. Additional protections may include Certificates of Confidentiality to further safeguard against disclosure of sensitive information.",ok
Human Clinical Trial Data,primary\llama-DMPs\Human Clinical Trial Data-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be monitored and managed by the study's principal investigator in collaboration with the institution's research administration office. Regular oversight meetings will occur quarterly during the active data collection phase and annually thereafter to ensure adherence to the plan, address any issues related to data sharing, and implement necessary updates as policies evolve.",ok
Clinical data from human research participants-NIA,primary\llama-DMPs\Clinical data from human research participants-NIA-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"The project anticipates generating a substantial amount of clinical data from electronic health records (EHRs) for approximately 15,000 patients in a primary care clinic. This includes demographic data, medical history, laboratory results, medications, physical exam findings, and cognitive exams. Additionally, for a subset of about 40 individuals, cognitive assessment data will be collected through validated assessment instruments. The primary goal is to utilize these clinical data to generate cognitive risk scores. Given the nature of EHR data and the specific cognitive assessments, the estimated amount of data will be significant, including but not limited to:
     - Demographic data: age, gender, ethnicity, etc.
     - Medical history: diagnoses, treatments, hospitalizations
     - Laboratory data: blood tests, imaging results
     - Medications: prescriptions, dosages
     - Physical exams: vital signs, physical condition assessments
     - Cognitive exams: results from validated cognitive assessment instruments",ok
Clinical data from human research participants-NIA,primary\llama-DMPs\Clinical data from human research participants-NIA-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All clinical data collected from EHRs and cognitive assessment data will be preserved and shared. The rationale behind sharing these data is to facilitate research into cognitive health and risk factors associated with aging, aligning with the mission of the National Institute on Aging (NIA). By making these data available, researchers can conduct studies that might lead to better understanding, prevention, and treatment of age-related cognitive decline. Given that all participants will provide consent for broad data sharing, it is anticipated that de-identified datasets will be made available to maximize utility while protecting participant privacy.",ok
Clinical data from human research participants-NIA,primary\llama-DMPs\Clinical data from human research participants-NIA-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","To facilitate interpretation and reuse of the scientific data, the following metadata and documentation will be made accessible:
     - Study protocols outlining data collection procedures
     - Data collection instruments (e.g., specific cognitive assessment tools used)
     - Data dictionaries explaining variable names, formats, and definitions
     - Documentation of any data transformations or cleaning processes applied to the raw data",ok
Clinical data from human research participants-NIA,primary\llama-DMPs\Clinical data from human research participants-NIA-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools, software, and/or code may be necessary for accessing or manipulating shared scientific data. For example, statistical analysis software (e.g., R, Python libraries like Pandas and NumPy) will be required to analyze the cognitive risk scores and clinical data. Additionally, data manipulation and cleaning might involve the use of specific programming languages or tools designed for handling large healthcare datasets. Access to these tools can typically be obtained through academic licenses or open-source repositories.",ok
Clinical data from human research participants-NIA,primary\llama-DMPs\Clinical data from human research participants-NIA-llama3.3.md,### Element 3: Standards:,"To ensure interoperability of datasets and resources, common data standards will be applied to the scientific data and associated metadata. Specifically, the project will adhere to the Health Level Seven International (HL7) standards for clinical and administrative data, and the Cognitive Atlas framework for cognitive assessment data. These standards will enable seamless integration with other research datasets and facilitate meta-analyses and comparative studies across different populations and research questions.",ok
Clinical data from human research participants-NIA,primary\llama-DMPs\Clinical data from human research participants-NIA-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,"The scientific data and metadata arising from the project will be archived in the National Institutes of Health’s (NIH) National Library of Medicine (NLM) repository, specifically through databases like PubMed or clinical trial registries when applicable, and potentially other discipline-specific repositories such as the Alzheimer's Disease Knowledge Portal for cognitive and dementia-related research.",ok
Clinical data from human research participants-NIA,primary\llama-DMPs\Clinical data from human research participants-NIA-llama3.3.md,2. **How scientific data will be findable and identifiable:**,"Scientific data will be made findable and identifiable via persistent unique identifiers (e.g., DOI - Digital Object Identifier) assigned by the repository where the data are archived, along with detailed metadata descriptions that include keywords, study titles, and investigator names.",ok
Clinical data from human research participants-NIA,primary\llama-DMPs\Clinical data from human research participants-NIA-llama3.3.md,3. **When and how long the scientific data will be made available:**,"The scientific data will be made available to other users no later than the time of publication of the main findings or at the end of the performance period, whichever comes first. The data are expected to remain available for a minimum of 10 years after the study’s completion to allow for extended research and validation studies.",ok
Clinical data from human research participants-NIA,primary\llama-DMPs\Clinical data from human research participants-NIA-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","While the project aims to maximize data sharing, factors such as informed consent limitations, privacy protections (especially for sensitive health information), and confidentiality agreements may impose certain restrictions on access, distribution, or reuse of the scientific data. However, given that participants will consent to broad data sharing, these limitations are anticipated to be minimal.",ok
Clinical data from human research participants-NIA,primary\llama-DMPs\Clinical data from human research participants-NIA-llama3.3.md,2. **Whether access to scientific data will be controlled:**,"Access to the scientific data will not be controlled beyond what is required for protecting participant privacy and ensuring compliance with regulatory requirements. Once archived in a public repository, the data will be accessible without need for approval, although some repositories may require registration or acceptance of terms of use.",ok
Clinical data from human research participants-NIA,primary\llama-DMPs\Clinical data from human research participants-NIA-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","To protect the privacy, rights, and confidentiality of human research participants, all shared data will be de-identified according to the HIPAA Privacy Rule, removing direct identifiers such as names, addresses, and Social Security numbers. Additionally, measures like data aggregation, anonymization, and encryption will be employed where necessary. The project may also apply for a Certificate of Confidentiality from the NIH to further safeguard sensitive information.",ok
Clinical data from human research participants-NIA,primary\llama-DMPs\Clinical data from human research participants-NIA-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be monitored and managed by the study’s Principal Investigator (PI), in collaboration with the institution’s research administration office. Regular oversight meetings will be held every six months to review data sharing progress, address any challenges or concerns, and ensure adherence to the plan’s guidelines and timelines. The PI will also work closely with the data management team to implement data standards, prepare datasets for sharing, and coordinate with repositories for data archiving.",ok
"Survey, interview, and biological data (tiered access)","primary\llama-DMPs\Survey, interview, and biological data (tiered access)-llama3.3.md",1. **Types and amount of scientific data expected to be generated in the project:**,"The proposed project involves collecting social, behavioral, and biological data through web-surveys, in-person interviews, and home health exams for approximately 13,000 participants (web-surveys and interviews) and 200 participants (home health exams), resulting in a substantial amount of qualitative and quantitative data.",ok
"Survey, interview, and biological data (tiered access)","primary\llama-DMPs\Survey, interview, and biological data (tiered access)-llama3.3.md","2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All data collected from web-surveys, interviews, and home health exams will be preserved and shared. The rationale for sharing these data is to contribute to the broader research community, facilitate replication studies, enable meta-analyses, and foster new research questions that can advance our understanding of aging. Given that all participants are consented for broad data sharing, this maximizes the potential impact of the study.",ok
"Survey, interview, and biological data (tiered access)","primary\llama-DMPs\Survey, interview, and biological data (tiered access)-llama3.3.md","3. **Metadata, other relevant data, and associated documentation:**","Metadata will include participant demographics, survey and interview protocols, home health exam procedures, and any additional information necessary to interpret the collected data correctly. Other relevant data may encompass environmental factors, lifestyle choices, and medical histories where applicable. Associated documentation will comprise study protocols, data collection instruments (e.g., survey questions), and data dictionaries explaining variable names and codes.",ok
"Survey, interview, and biological data (tiered access)","primary\llama-DMPs\Survey, interview, and biological data (tiered access)-llama3.3.md","### Element 2: Related Tools, Software and/or Code:","Specialized tools and software needed to access or manipulate shared scientific data include statistical analysis packages like R or SPSS and potentially data visualization tools. The specific software required will be documented in the metadata to ensure that future users can appropriately analyze and interpret the data. These tools are widely available in the academic community, either through institutional licenses or free versions.",ok
"Survey, interview, and biological data (tiered access)","primary\llama-DMPs\Survey, interview, and biological data (tiered access)-llama3.3.md",### Element 3: Standards:,"The scientific data and associated metadata will apply common data standards to enable interoperability. Specifically, data will be formatted according to the Data Documentation Initiative (DDI) standard for social science data, which is widely adopted in similar longitudinal studies. This standard ensures that data are properly described, making them understandable and usable by other researchers.",ok
"Survey, interview, and biological data (tiered access)","primary\llama-DMPs\Survey, interview, and biological data (tiered access)-llama3.3.md",1. **Repository where scientific data and metadata will be archived:**,"The scientific data and metadata arising from the project will be archived in the National Archive of Computerized Data on Aging (NACDA), which is a repository recommended by the NIH for social science data related to aging.",ok
"Survey, interview, and biological data (tiered access)","primary\llama-DMPs\Survey, interview, and biological data (tiered access)-llama3.3.md",2. **How scientific data will be findable and identifiable:**,"Data will be made findable through the use of persistent unique identifiers (DOIs) assigned by the repository, facilitating easy citation and access. The metadata will also include standard indexing tools such as keywords and study descriptions to enhance discoverability.",ok
"Survey, interview, and biological data (tiered access)","primary\llama-DMPs\Survey, interview, and biological data (tiered access)-llama3.3.md",3. **When and how long the scientific data will be made available:**,"The scientific data will be made available no later than the time of publication of the main findings or within one year after the completion of data collection, whichever comes first. The data will remain available for at least 10 years post-collection to allow for extensive use by the research community.",ok
"Survey, interview, and biological data (tiered access)","primary\llama-DMPs\Survey, interview, and biological data (tiered access)-llama3.3.md","1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","Given that participants are consented for broad data sharing, the primary factor affecting access is ensuring that data are de-identified to protect participant privacy and confidentiality. There are no anticipated limitations on data sharing beyond standard protections for human subjects research.",ok
"Survey, interview, and biological data (tiered access)","primary\llama-DMPs\Survey, interview, and biological data (tiered access)-llama3.3.md",2. **Whether access to scientific data will be controlled:**,"Access to the scientific data will not be controlled beyond what is required for protecting human subjects; once archived, data will be openly available through the designated repository without need for additional approval.",ok
"Survey, interview, and biological data (tiered access)","primary\llama-DMPs\Survey, interview, and biological data (tiered access)-llama3.3.md","3. **Protections for privacy, rights, and confidentiality of human research participants:**","To protect participant privacy, rights, and confidentiality, all shared data will be de-identified following best practices for removing personal health information (PHI) as per HIPAA guidelines. Additionally, the study will operate under a Certificate of Confidentiality to further safeguard against disclosure of sensitive information.",ok
"Survey, interview, and biological data (tiered access)","primary\llama-DMPs\Survey, interview, and biological data (tiered access)-llama3.3.md",### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be monitored and managed by the project's Principal Investigator in conjunction with the institution's data management office. Oversight will occur on a bi-annual basis, with adjustments to the plan made as necessary to ensure adherence to NIH guidelines and to reflect any changes in data sharing best practices or policies.",ok
Non-human data (primates),primary\llama-DMPs\Non-human data (primates)-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"The proposed work will generate a significant amount of raw video, activity, and cardiac physiological files. From these primary data sources, we will derive behavioral data and autonomic nervous system reactivity data. The total number of subjects is anticipated to be N=500 across multiple test points. Given this scope, the estimated amount of scientific data generated is substantial, requiring careful management and storage considerations.",ok
Non-human data (primates),primary\llama-DMPs\Non-human data (primates)-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All raw video, activity, cardiac physiological files, along with derived behavioral and autonomic nervous system reactivity data, will be preserved and shared. The rationale for sharing these data is to facilitate transparency, reproducibility, and further research into aging mechanisms, aligning with the NIA's mission to understand aspects of aging and age-related diseases. Sharing these data will enable other researchers to explore new hypotheses, validate findings, and accelerate discovery in the field.",ok
Non-human data (primates),primary\llama-DMPs\Non-human data (primates)-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","To facilitate interpretation and reuse of the scientific data, we will make accessible the following metadata and documentation: 
     - Study protocols
     - Data collection instruments (e.g., questionnaires, sensor specifications)
     - Data processing and analysis scripts
     - Detailed descriptions of participant demographics and selection criteria
     - Information on data quality control measures
     These resources will be crucial for understanding the context, limitations, and potential applications of the shared data.",ok
Non-human data (primates),primary\llama-DMPs\Non-human data (primates)-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools, software, and code are indeed necessary to access or manipulate the shared scientific data. Specifically, users may need access to video analysis software (e.g., OpenCV), statistical analysis packages (e.g., R, Python libraries like Pandas and NumPy), and possibly custom scripts developed for this project. These tools will be accessible through open-source repositories (e.g., GitHub) or via links provided in the metadata documentation associated with the shared data.",ok
Non-human data (primates),primary\llama-DMPs\Non-human data (primates)-llama3.3.md,### Element 3: Standards:,"To enable interoperability of datasets and resources, we will apply common data standards relevant to the types of data collected. For video files, MP4 format will be used; for physiological data, the WFDB (Waveform Database) software package's standard will guide formatting. Behavioral data will be structured according to widely accepted psychological and behavioral assessment norms. Since no single consensus standard covers all aspects of our diverse dataset comprehensively, we will adhere to discipline-specific standards where applicable and document deviations or custom approaches in the associated metadata.",ok
Non-human data (primates),primary\llama-DMPs\Non-human data (primates)-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,"The scientific data and metadata arising from this project will be archived in the National Institutes of Health's National Library of Medicine (NLM) repository, specifically leveraging resources like the Database of Genotypes and Phenotypes (dbGaP) for human subjects data when appropriate, or other designated repositories that align with NIH recommendations for data sharing.",ok
Non-human data (primates),primary\llama-DMPs\Non-human data (primates)-llama3.3.md,2. **How scientific data will be findable and identifiable:**,"Scientific data will be made findable and identifiable through the use of persistent unique identifiers (e.g., DOIs - Digital Object Identifiers) and standard indexing tools such as those used by PubMed or specific to the chosen repository.",ok
Non-human data (primates),primary\llama-DMPs\Non-human data (primates)-llama3.3.md,3. **When and how long the scientific data will be made available:**,"The scientific data will be made available no later than the time of publication of the main findings from the dataset or at the end of the performance period, whichever comes first. The data will remain accessible for a minimum of 10 years following the end of the project to maximize its utility and impact on the research community.",ok
Non-human data (primates),primary\llama-DMPs\Non-human data (primates)-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","While we aim to maximize data sharing, limitations may arise due to informed consent restrictions, privacy and confidentiality protections for human subjects, and potential intellectual property considerations related to custom software or methodologies developed during the project. These limitations will be clearly documented in the metadata and associated documentation.",ok
Non-human data (primates),primary\llama-DMPs\Non-human data (primates)-llama3.3.md,2. **Whether access to scientific data will be controlled:**,"Access to certain components of the scientific data may be controlled, particularly if they contain personally identifiable information (PII) or other sensitive material. In such cases, data will be de-identified or made available through a controlled access mechanism provided by the repository.",ok
Non-human data (primates),primary\llama-DMPs\Non-human data (primates)-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","To protect the privacy, rights, and confidentiality of human research participants, all shared data will be de-identified. Additionally, we will obtain a Certificate of Confidentiality from the NIH to further safeguard against disclosure of sensitive information. Study protocols will also include explicit language regarding confidentiality and privacy protections in the informed consent process.",ok
Non-human data (primates),primary\llama-DMPs\Non-human data (primates)-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be monitored and managed by the Principal Investigator (PI) in collaboration with the institution's research data management office. Regular oversight meetings will occur at least quarterly to review progress, address any challenges in data sharing, and ensure adherence to the plan's timelines and standards. The PI will also work closely with the NIH and the designated data repository to facilitate smooth implementation of the data sharing aspects of this project.",ok
Secondary data analysis-NIA,primary\llama-DMPs\Secondary data analysis-NIA-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"The proposed work will utilize existing publicly available data from the Health and Retirement Study (HRS) and HRS-linked Medicare data accessible through a data use agreement. The types of data include survey responses, administrative claims data, and potentially linked genetic information, if available. Given that no new data collection is planned, the amount of scientific data generated will be dependent on the secondary analyses performed.",ok
Secondary data analysis-NIA,primary\llama-DMPs\Secondary data analysis-NIA-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All derived datasets from the secondary analysis of HRS and HRS-linked Medicare data will be preserved and shared. The rationale for sharing these data is to maximize research efficiency, facilitate replication studies, and encourage further investigations into aging mechanisms and outcomes, aligning with NIA’s mission.",ok
Secondary data analysis-NIA,primary\llama-DMPs\Secondary data analysis-NIA-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","Metadata will include variable descriptions, data dictionaries, study protocols, and any modifications made to the original datasets during analysis (e.g., data cleaning steps, imputation methods). Associated documentation will comprise study reports, publications, and presentation materials related to the project outcomes.",ok
Secondary data analysis-NIA,primary\llama-DMPs\Secondary data analysis-NIA-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools and software needed for access or manipulation of shared scientific data include statistical analysis packages like R or SAS, potentially specific libraries for handling large datasets (e.g., dplyr in R), and data visualization tools. Access to these tools can be obtained through academic licenses or open-source repositories.",ok
Secondary data analysis-NIA,primary\llama-DMPs\Secondary data analysis-NIA-llama3.3.md,### Element 3: Standards:,"Common data standards applied will include those recommended by the NIH for demographic and clinical data, such as the use of standardized vocabularies (e.g., ICD-10 for medical conditions) and data formats (e.g., CSV for tabular data). For metadata, standards like the Data Documentation Initiative (DDI) will be considered to enable interoperability and facilitate understanding of the datasets.",ok
Secondary data analysis-NIA,primary\llama-DMPs\Secondary data analysis-NIA-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,"The National Archive of Computerized Data on Aging (NACDA), housed within the Inter-university Consortium for Political and Social Research (ICPSR), is identified as a suitable repository for archiving scientific data and metadata arising from this project, given its relevance to aging research.",ok
Secondary data analysis-NIA,primary\llama-DMPs\Secondary data analysis-NIA-llama3.3.md,2. **How scientific data will be findable and identifiable:**,Scientific data will be made findable through the assignment of a Digital Object Identifier (DOI) and indexed in search engines like Google Dataset Search or specific databases related to aging research. Descriptive metadata will enable easy identification of the datasets.,ok
Secondary data analysis-NIA,primary\llama-DMPs\Secondary data analysis-NIA-llama3.3.md,3. **When and how long the scientific data will be made available:**,"Derived datasets from this project will be made available no later than the time of publication of the main findings or at the end of the performance period, whichever comes first. Data will remain accessible for a minimum of 10 years after the project’s completion to allow for longitudinal analyses and replication studies.",ok
Secondary data analysis-NIA,primary\llama-DMPs\Secondary data analysis-NIA-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","Given that all research participants are consented for broad data sharing, limitations on data sharing will primarily stem from privacy and confidentiality protections. Specifically, any direct identifiers will be removed, and sensitive information (e.g., exact addresses) will be aggregated or suppressed to protect participant confidentiality.",ok
Secondary data analysis-NIA,primary\llama-DMPs\Secondary data analysis-NIA-llama3.3.md,2. **Whether access to scientific data will be controlled:**,Access to the shared datasets will not require additional approval beyond what is typically required by the chosen repository for accessing similar datasets.,ok
Secondary data analysis-NIA,primary\llama-DMPs\Secondary data analysis-NIA-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","To protect participant privacy, all shared datasets will undergo rigorous de-identification procedures. This includes but is not limited to removing direct identifiers (e.g., names, social security numbers), aggregating or suppressing sensitive variables, and applying statistical disclosure limitation methods as necessary.",ok
Secondary data analysis-NIA,primary\llama-DMPs\Secondary data analysis-NIA-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be monitored by the project’s Principal Investigator in collaboration with the institution’s research data management office. Regular checks (every 6 months) will ensure adherence to the plan, including timely deposition of datasets into the designated repository and maintenance of accurate metadata. Any deviations or challenges encountered during implementation will be addressed through adjustments to the plan as needed, with documentation of such changes kept on record.",ok
Survey and interview data-NIA,primary\llama-DMPs\Survey and interview data-NIA-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"This project anticipates generating several types of scientific data, including physical activity data from accelerometers, survey responses characterizing caregiver well-being, and digital recordings of participant responses to semi-structured interviews. The estimated amount of data includes accelerometer readings for 250 participants across three timepoints, survey responses from the same cohort, and approximately 250 digital recordings of interviews, each expected to be about 60 minutes long.",ok
Survey and interview data-NIA,primary\llama-DMPs\Survey and interview data-NIA-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All scientific data generated from this project, including physical activity data, survey responses, and interview recordings (in de-identified form), will be preserved and shared. The rationale for sharing these data is to facilitate secondary analyses, promote transparency and reproducibility in research, and enable other researchers to build upon our findings, ultimately contributing to a better understanding of caregiver well-being and its relationship with physical activity.",ok
Survey and interview data-NIA,primary\llama-DMPs\Survey and interview data-NIA-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","To facilitate interpretation of the scientific data, we will make accessible metadata such as participant demographics, data collection protocols, survey instruments, interview guides, and detailed descriptions of the accelerometer data collection procedures. Associated documentation will include study protocols, informed consent forms, and data dictionaries.",ok
Survey and interview data-NIA,primary\llama-DMPs\Survey and interview data-NIA-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools and software needed to access or manipulate shared scientific data include statistical analysis packages (e.g., R, SPSS) for survey and accelerometer data, and transcription software (e.g., NVivo) for analyzing interview recordings. These tools are widely available in the academic community, and specific versions used will be documented in our methodology descriptions.",ok
Survey and interview data-NIA,primary\llama-DMPs\Survey and interview data-NIA-llama3.3.md,### Element 3: Standards:,"Common data standards applied to the scientific data and associated metadata will include those recommended by the NIH for physical activity measurement and survey research, as well as standards for qualitative data such as those outlined by the Qualitative Data Repository. For accelerometer data, we will adhere to the standards set by the National Cancer Institute's Physical Activity Measurement Guidelines. Survey data will be formatted according to the Questionnaire Design guidelines. Since no single consensus standard exists for all types of data collected in this project (especially qualitative interview data), we will follow best practices in the field and ensure that our metadata and documentation are comprehensive and transparent.",ok
Survey and interview data-NIA,primary\llama-DMPs\Survey and interview data-NIA-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,"Scientific data and metadata arising from this project will be archived in a public repository such as the National Institutes of Health’s National Library of Medicine (NLM) or other NIH-approved repositories like the Interuniversity Consortium for Political and Social Research (ICPSR) for social science data, ensuring long-term preservation and access.",ok
Survey and interview data-NIA,primary\llama-DMPs\Survey and interview data-NIA-llama3.3.md,2. **How scientific data will be findable and identifiable:**,"The scientific data will be made findable and identifiable through the use of persistent unique identifiers such as DOIs (Digital Object Identifiers), which will be assigned upon deposition into the chosen repository. Data will also be indexed using standard keywords and descriptors relevant to caregiver well-being, physical activity, and aging research.",ok
Survey and interview data-NIA,primary\llama-DMPs\Survey and interview data-NIA-llama3.3.md,3. **When and how long the scientific data will be made available:**,"The scientific data will be made available no later than the time of publication of the main findings or at the end of the performance period, whichever comes first. The data are expected to remain accessible for a minimum of 10 years after the project’s completion, as per NIH guidelines and repository policies, to allow for long-term research and analysis.",ok
Survey and interview data-NIA,primary\llama-DMPs\Survey and interview data-NIA-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","While we aim to maximize data sharing, factors such as participant privacy and confidentiality may limit certain aspects of data accessibility. All participants will provide broad consent for data sharing, but measures will be taken to de-identify data, especially for sensitive information shared during interviews.",ok
Survey and interview data-NIA,primary\llama-DMPs\Survey and interview data-NIA-llama3.3.md,2. **Whether access to scientific data will be controlled:**,"Access to the scientific data will not be controlled beyond what is required for protecting participant privacy and confidentiality. Once deposited in a public repository, data will be available for download and use by other researchers without need for approval, except where specified by repository policies.",ok
Survey and interview data-NIA,primary\llama-DMPs\Survey and interview data-NIA-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","To protect the privacy, rights, and confidentiality of human research participants, all identifiable information will be removed from shared datasets (de-identification). We will also obtain a Certificate of Confidentiality from the NIH to further safeguard against disclosure of sensitive information. Informed consent documents will clearly outline the risks and benefits of data sharing.",ok
Survey and interview data-NIA,primary\llama-DMPs\Survey and interview data-NIA-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be monitored and managed by the Principal Investigator (PI) in collaboration with the research team, including a designated data manager. Regular checks (every 6 months) will ensure that data collection, storage, and sharing practices adhere to the outlined plan and relevant regulations. The institution’s Office of Research Compliance and Integrity will also provide oversight and support as needed to ensure adherence to NIH policies and ethical standards.",ok
Human clinical and genomic data-NIA,primary\llama-DMPs\Human clinical and genomic data-NIA-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"This study aims to generate whole genome sequencing (WGS) data from human blood samples of 3,200 non-Hispanic White (NHW) cases with Late-onset Alzheimer’s Disease (LOAD) and matched controls. Additionally, GWAS and exome sequencing data will be generated using blood samples from diverse populations: 1,000 African American (AA) cases and matched controls, and 1,343 Hispanic (HI) cases and matched controls. Familial WGS will also be completed in 1,012 NHW and HI individuals, respectively. The estimated total data size is approximately 30 TB. Associated phenotypic data, including clinical subtypes, endophenotypes, and biomarkers, will also be collected and shared.",ok
Human clinical and genomic data-NIA,primary\llama-DMPs\Human clinical and genomic data-NIA-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All generated WGS, GWAS, exome sequencing, and associated phenotypic data will be preserved and shared. The rationale for sharing these data is to facilitate research into the genetic underpinnings of Alzheimer’s Disease, particularly in diverse populations, thereby accelerating the discovery of potential therapeutic targets and improving our understanding of disease mechanisms. Broad sharing of these data will enable other researchers to validate findings, explore new hypotheses, and combine data from multiple studies to achieve more robust conclusions.",ok
Human clinical and genomic data-NIA,primary\llama-DMPs\Human clinical and genomic data-NIA-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","The metadata to be shared include sample identifiers, sequencing protocols, data processing pipelines, and quality control metrics. Other relevant data include demographic information (age, sex, ethnicity), clinical diagnoses, and biomarker measurements. Associated documentation will comprise study protocols, informed consent forms, and detailed descriptions of the methodologies used for data generation and analysis.",ok
Human clinical and genomic data-NIA,primary\llama-DMPs\Human clinical and genomic data-NIA-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools, software, and/or code needed to access or manipulate shared scientific data include bioinformatics pipelines for variant calling (e.g., GATK), genotyping (e.g., PLINK), and data analysis (e.g., R, Python libraries like Pandas and NumPy). These can be accessed through public repositories (e.g., GitHub) or downloaded from official software websites. Documentation on how to use these tools will be provided alongside the shared data.",ok
Human clinical and genomic data-NIA,primary\llama-DMPs\Human clinical and genomic data-NIA-llama3.3.md,### Element 3: Standards:,"Common data standards applied to the scientific data and associated metadata include those recommended by the Global Alliance for Genomics and Health (GA4GH) for genomic data, and the PhenX toolkit for phenotypic data. These standards enable interoperability of datasets and resources, facilitating combination and comparison of data across studies. Specifically, VCF (Variant Call Format) will be used for genetic variant data, and standardized ontologies (e.g., HPO for human phenotypes) will be applied to phenotypic descriptions.",ok
Human clinical and genomic data-NIA,primary\llama-DMPs\Human clinical and genomic data-NIA-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,"Scientific data and metadata arising from the project will be archived in the Database of Genotypes and Phenotypes (dbGaP) and possibly other NIH-approved repositories, following the guidelines outlined by the NIH for data sharing.",ok
Human clinical and genomic data-NIA,primary\llama-DMPs\Human clinical and genomic data-NIA-llama3.3.md,2. **How scientific data will be findable and identifiable:**,"The scientific data will be made findable and identifiable through the use of persistent unique identifiers (e.g., DOIs, accession numbers) and standard indexing tools available in the chosen repository.",ok
Human clinical and genomic data-NIA,primary\llama-DMPs\Human clinical and genomic data-NIA-llama3.3.md,3. **When and how long the scientific data will be made available:**,"The scientific data will be made available to other users no later than the time of an associated publication or end of the performance period, whichever comes first. Data will remain available for a minimum of 10 years after the project's completion, as per the repository's data retention policies and in compliance with NIH guidelines.",ok
Human clinical and genomic data-NIA,primary\llama-DMPs\Human clinical and genomic data-NIA-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","Given that all research participants will be consented for broad data sharing, limitations on access are primarily related to protecting participant privacy and confidentiality. Data will be de-identified before sharing, and access may be controlled through dbGaP's authorized access mechanism for sensitive data.",ok
Human clinical and genomic data-NIA,primary\llama-DMPs\Human clinical and genomic data-NIA-llama3.3.md,2. **Whether access to scientific data will be controlled:**,"Access to the scientific data will be controlled through mechanisms provided by the chosen repository (e.g., dbGaP), requiring users to register and agree to terms of use before accessing sensitive or identifiable data.",ok
Human clinical and genomic data-NIA,primary\llama-DMPs\Human clinical and genomic data-NIA-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","To protect participant privacy, rights, and confidentiality, all shared data will be de-identified according to the HIPAA Privacy Rule's standards for de-identification. Additionally, the study will obtain a Certificate of Confidentiality from the NIH to further safeguard against disclosure of sensitive information.",ok
Human clinical and genomic data-NIA,primary\llama-DMPs\Human clinical and genomic data-NIA-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be monitored and managed by the Principal Investigator (PI) in collaboration with the institution's data management office. Regular reviews (at least annually) will ensure that data are being collected, stored, and shared according to the plan and NIH policies. The PI and designated data managers will oversee data quality control, ensure timely sharing of data through approved repositories, and address any issues or concerns related to data access or use.",ok
Non-human data (rodents)-NIA,primary\llama-DMPs\Non-human data (rodents)-NIA-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"The study will generate multimodal data from 50 to 80 mouse subjects, combining electrophysiological, behavioral, and imaging modalities. The expected data types include:
     - Electrophysiology data: Raw extracellular voltage recordings and processed spike time data, estimated at 100–1000 GB.
     - Behavioral data: Raw video frames and processed positional and heading data for spatial navigation tasks, estimated at 10–100 GB.
     - Imaging data: 3-color image stacks of immunostained mouse brain tissue from confocal microscopy, verifying probe placement in the hippocampus, estimated at 1–10 GB.",ok
Non-human data (rodents)-NIA,primary\llama-DMPs\Non-human data (rodents)-NIA-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All generated data (electrophysiology, behavioral, and imaging) will be preserved and shared. The rationale is to facilitate transparency, reproducibility, and further research into hippocampal function, potentially leading to advancements in understanding neurological disorders and aging processes.",ok
Non-human data (rodents)-NIA,primary\llama-DMPs\Non-human data (rodents)-NIA-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","Metadata will include experimental protocols, animal subject information (age, sex, strain), electrode placement coordinates, and behavioral task descriptions. Other relevant data will encompass environmental conditions during experiments (temperature, humidity) and equipment settings (microscope, recording devices). Associated documentation will include study protocols, data collection instruments, and detailed methodologies for data processing and analysis.",ok
Non-human data (rodents)-NIA,primary\llama-DMPs\Non-human data (rodents)-NIA-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools and software needed to access or manipulate shared scientific data include:
     - Electrophysiology analysis software (e.g., Spike2, MATLAB).
     - Video analysis software for behavioral data (e.g., ANY-maze, EthoVision).
     - Image processing software for microscopy images (e.g., ImageJ, Fiji).
   These tools can be accessed through their respective websites or academic licensing agreements.",ok
Non-human data (rodents)-NIA,primary\llama-DMPs\Non-human data (rodents)-NIA-llama3.3.md,### Element 3: Standards:,"Common data standards to be applied include:
     - Neurodata Without Borders (NWB) for electrophysiology and behavioral data.
     - Open Microscopy Environment (OME) for imaging data.
   These standards enable interoperability of datasets, facilitating collaborative research and data reuse. For metadata, we will adhere to the FAIR principles (Findable, Accessible, Interoperable, Reusable), ensuring that our data is properly described, licensed, and accessible.",ok
Non-human data (rodents)-NIA,primary\llama-DMPs\Non-human data (rodents)-NIA-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,"Scientific data and metadata will be archived in the National Institute of Mental Health (NIMH) Data Archive (NDA), which is compatible with the standards mentioned above and allows for controlled access to sensitive data.",ok
Non-human data (rodents)-NIA,primary\llama-DMPs\Non-human data (rodents)-NIA-llama3.3.md,2. **How scientific data will be findable and identifiable:**,"Data will be made findable through the use of persistent unique identifiers (DOIs) assigned by the repository, along with detailed metadata descriptions and standardized keywords facilitating discovery.",ok
Non-human data (rodents)-NIA,primary\llama-DMPs\Non-human data (rodents)-NIA-llama3.3.md,3. **When and how long the scientific data will be made available:**,"Scientific data will be made available no later than the time of publication of the main findings or end of the performance period, whichever comes first. Data will remain accessible for a minimum of 10 years following the end of the project to allow for extended research and validation opportunities.",ok
Non-human data (rodents)-NIA,primary\llama-DMPs\Non-human data (rodents)-NIA-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","Given that our study involves animal subjects rather than human participants, factors affecting access are primarily related to ensuring the integrity and security of the data during sharing and storage. No limitations based on informed consent or privacy concerns are applicable.",ok
Non-human data (rodents)-NIA,primary\llama-DMPs\Non-human data (rodents)-NIA-llama3.3.md,2. **Whether access to scientific data will be controlled:**,"Access to certain aspects of the data, particularly detailed experimental protocols and raw data files, may be controlled through the NDA's access request mechanism to ensure that data are used appropriately and respectfully.",ok
Non-human data (rodents)-NIA,primary\llama-DMPs\Non-human data (rodents)-NIA-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","As this project involves mouse subjects, protections for human participant privacy, rights, and confidentiality are not applicable. However, all experiments will be conducted in accordance with institutional animal care and use guidelines to ensure ethical treatment of animals.",ok
Non-human data (rodents)-NIA,primary\llama-DMPs\Non-human data (rodents)-NIA-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be monitored and managed by the Principal Investigator (PI) and a designated data manager. Regular oversight meetings will occur quarterly to review data generation, storage, and sharing processes. The institution's research integrity office will also conduct annual reviews to ensure adherence to the plan and address any issues or updates as necessary.",ok
Clinical data (human biospecimens),primary\llama-DMPs\Clinical data (human biospecimens)-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"This study aims to collect demographic and clinical data from 200 amyloid-positive, cognitively normal older adults with symptomatic insomnia. The types of clinical data include amyloid-beta (Aβ), tau, phosphorylated tau, NPTX2, sTREM2, and NfL from cerebrospinal fluid (CSF); Aβ, tau, and phosphorylated tau from plasma; and cognitive status assessments. We anticipate generating approximately 200 datasets for each type of clinical data, along with associated demographic information.",ok
Clinical data (human biospecimens),primary\llama-DMPs\Clinical data (human biospecimens)-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All collected scientific data, including demographic information, CSF and plasma biomarkers, and cognitive assessments, will be preserved and shared. The rationale for sharing these data is to facilitate research into the relationship between amyloid positivity, insomnia, and cognitive decline in older adults, thereby advancing our understanding of Alzheimer's disease and related dementias.",ok
Clinical data (human biospecimens),primary\llama-DMPs\Clinical data (human biospecimens)-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","Metadata will include participant identifiers, age, sex, and collection dates for each sample. Other relevant data will encompass study protocols, data collection instruments (e.g., questionnaires, cognitive tests), and analytical methods used to process biomarker samples. Associated documentation will be made accessible to facilitate interpretation of the scientific data.",ok
Clinical data (human biospecimens),primary\llama-DMPs\Clinical data (human biospecimens)-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools and software needed to access or manipulate shared scientific data include statistical analysis packages (e.g., R, Python libraries) for handling large datasets and specific algorithms for biomarker analysis. These tools are widely available in the academic community.",ok
Clinical data (human biospecimens),primary\llama-DMPs\Clinical data (human biospecimens)-llama3.3.md,### Element 3: Standards:,"Common data standards applied to the scientific data and associated metadata will include those recommended by the National Institute on Aging (NIA) for Alzheimer's disease research, such as the Alzheimer’s Disease Neuroimaging Initiative (ADNI) protocols for biomarker collection and analysis. These standards enable interoperability of datasets and resources.",ok
Clinical data (human biospecimens),primary\llama-DMPs\Clinical data (human biospecimens)-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,Scientific data and metadata arising from the project will be archived in the National Institute on Aging Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS) or a similar designated repository that aligns with NIH guidelines for data sharing.,ok
Clinical data (human biospecimens),primary\llama-DMPs\Clinical data (human biospecimens)-llama3.3.md,2. **How scientific data will be findable and identifiable:**,"The scientific data will be made findable and identifiable via persistent unique identifiers (e.g., DOI numbers) and standard indexing tools compatible with the chosen repository, ensuring ease of access for other researchers.",ok
Clinical data (human biospecimens),primary\llama-DMPs\Clinical data (human biospecimens)-llama3.3.md,3. **When and how long the scientific data will be made available:**,"The scientific data will be made available to other users no later than the time of an associated publication or end of the performance period, whichever comes first, and will remain available for at least 10 years following the completion of the project to maximize its utility for the research community.",ok
Clinical data (human biospecimens),primary\llama-DMPs\Clinical data (human biospecimens)-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","Given that all participants will provide consent for broad data sharing, factors affecting access are minimal. However, protections for privacy and confidentiality will be maintained through de-identification of datasets before sharing.",ok
Clinical data (human biospecimens),primary\llama-DMPs\Clinical data (human biospecimens)-llama3.3.md,2. **Whether access to scientific data will be controlled:**,"Access to the scientific data will not be controlled beyond the standard protocols of the repository used for archiving, which may include registration or acceptance of terms of use.",ok
Clinical data (human biospecimens),primary\llama-DMPs\Clinical data (human biospecimens)-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","To protect the privacy, rights, and confidentiality of human research participants, all shared data will be de-identified. Additionally, a Certificate of Confidentiality will be obtained to further safeguard against disclosure of sensitive information.",ok
Clinical data (human biospecimens),primary\llama-DMPs\Clinical data (human biospecimens)-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be monitored and managed by the Principal Investigator (PI) in collaboration with the institution's data management office. Regular checks (at least annually) will ensure that data are being properly collected, stored, and shared according to the plan and NIH guidelines. The PI will also be responsible for reporting any deviations from the plan to the funding agency.",ok
Drug discovery including intellectual property,primary\llama-DMPs\Drug discovery including intellectual property-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"The project is estimated to generate a significant amount of scientific data, including: 
     - Design, production, characterization, and purification protocols for 30 Compound A analogs.
     - In vitro and cell-based assay data for 30 Compound A analogs.
     - Substance stability data, in vitro toxicology data, and in vivo toxicology data (using 6 WT mice per dose, with 5 doses) for 10 selected compounds.
     - Pharmacokinetics (ADME) data for 3-4 compounds (using 10 5xFAD mice per dose, with 4 doses).
     - Preclinical positron emission tomography (PET) imaging data for 2-3 compounds (using 15 WT or 5xFAD mice per compound).",ok
Drug discovery including intellectual property,primary\llama-DMPs\Drug discovery including intellectual property-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All scientific data generated from this project will be preserved and shared. The rationale is to facilitate transparency, reproducibility, and accelerated discovery in the field of aging research. Sharing these data will enable other researchers to build upon our findings, validate our results, and explore new hypotheses related to Compound A analogs.",ok
Drug discovery including intellectual property,primary\llama-DMPs\Drug discovery including intellectual property-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","The following metadata, other relevant data, and associated documentation will be made accessible:
     - Study protocols
     - Data collection instruments
     - compound characterization data (e.g., structure, purity)
     - Assay descriptions and results
     - PET imaging protocols and analysis methods
     - Mouse strain and breeding information
     - Dose response curves for toxicology studies",ok
Drug discovery including intellectual property,primary\llama-DMPs\Drug discovery including intellectual property-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools and software needed to access or manipulate shared scientific data include:
     - GraphPad Prism for dose-response curve analysis
     - ImageJ for PET imaging analysis
     - ChemDraw for chemical structure drawing and editing
     - These tools are widely used in the field and can be accessed through institutional licenses or free versions.",ok
Drug discovery including intellectual property,primary\llama-DMPs\Drug discovery including intellectual property-llama3.3.md,### Element 3: Standards:,"The following common data standards will be applied to ensure interoperability of datasets and resources:
     - MIABE (Minimum Information About a Bioactive Entity) for compound characterization
     - MIACA (Minimum Information About a Cellular Assay) for in vitro assay data
     - ToxML for toxicology data reporting
     - These standards are recognized within the biomedical research community and will facilitate comparison and integration of our data with existing datasets.",ok
Drug discovery including intellectual property,primary\llama-DMPs\Drug discovery including intellectual property-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,"Scientific data and metadata arising from this project will be archived in publicly accessible repositories such as:
     - PubChem for compound structures and assay data
     - Figshare or Zenodo for other types of data (e.g., PET images, toxicology reports)
     - These repositories are recognized by the NIH and provide long-term preservation and access to scientific data.",ok
Drug discovery including intellectual property,primary\llama-DMPs\Drug discovery including intellectual property-llama3.3.md,2. **How scientific data will be findable and identifiable:**,"Scientific data will be made findable and identifiable through:
     - Assignment of DOI (Digital Object Identifiers) for each dataset
     - Use of standardized keywords and ontology terms in metadata descriptions
     - Indexing in relevant databases and search engines",ok
Drug discovery including intellectual property,primary\llama-DMPs\Drug discovery including intellectual property-llama3.3.md,3. **When and how long the scientific data will be made available:**,"Scientific data will be made available no later than the time of publication of the associated manuscript or within 12 months of the project end date, whichever comes first. Data will remain accessible for a minimum of 10 years after the project completion to ensure their continued utility and accessibility to the research community.",ok
Drug discovery including intellectual property,primary\llama-DMPs\Drug discovery including intellectual property-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","The primary factor affecting access is ensuring that all shared data are properly de-identified to protect animal welfare and research participant confidentiality. Additionally, considerations related to intellectual property may apply for certain compound structures and associated protocols.",ok
Drug discovery including intellectual property,primary\llama-DMPs\Drug discovery including intellectual property-llama3.3.md,2. **Whether access to scientific data will be controlled:**,"Access to the scientific data will not be controlled beyond standard repository access controls (e.g., login requirements for some datasets). However, for sensitive or potentially patentable information, a embargo period may be applied prior to public release.",ok
Drug discovery including intellectual property,primary\llama-DMPs\Drug discovery including intellectual property-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","Although this project primarily involves animal models, any future studies involving human subjects will adhere strictly to guidelines protecting participant privacy, rights, and confidentiality, including but not limited to obtaining informed consent, using de-identification methods where applicable, and applying for Certificates of Confidentiality as necessary.",ok
Drug discovery including intellectual property,primary\llama-DMPs\Drug discovery including intellectual property-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Plan will be monitored and managed by the Principal Investigator (PI) in collaboration with the research institution’s data management office. Regular checks (every 6 months) will be performed to ensure that all generated data are properly documented, stored, and shared according to the outlined timeline and standards. The PI will also oversee the preparation of Data Management and Sharing reports as required by the NIH.",ok
HeLa Cell Whole Genome Sequence (DNA or RNA),primary\llama-DMPs\HeLa Cell Whole Genome Sequence (DNA or RNA)-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"The project aims to generate high-fidelity (HiFi) long-read whole-genome sequencing data from a single human HeLa cell line. The total expected data output is approximately 700 megabytes (MB), which will capture the complete genome of the HeLa cell line with high-resolution coverage. The sequencing will be performed using the PacBio platform, known for its high-accuracy long reads suitable for resolving complex genomic regions.",ok
HeLa Cell Whole Genome Sequence (DNA or RNA),primary\llama-DMPs\HeLa Cell Whole Genome Sequence (DNA or RNA)-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All generated whole-genome sequencing data will be preserved and shared. The rationale behind this decision is to contribute to the scientific community's understanding of the HeLa cell line's genome, facilitating future research and potentially leading to breakthroughs in fields such as cancer biology and genomic medicine. Sharing these data aligns with the principles of transparency, reproducibility, and collaboration that underpin modern biomedical research.",ok
HeLa Cell Whole Genome Sequence (DNA or RNA),primary\llama-DMPs\HeLa Cell Whole Genome Sequence (DNA or RNA)-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","Associated metadata will include sequencing protocols, sample preparation methods, and data analysis pipelines used in the project. Other relevant data may encompass quality control metrics for the sequencing runs and any additional experimental data that provide context to the genomic findings. Documentation such as study protocols, consent forms (given that this proposal involves human participants who have been consented for broad data sharing), and detailed descriptions of bioinformatic tools and parameters used will also be made accessible.",ok
HeLa Cell Whole Genome Sequence (DNA or RNA),primary\llama-DMPs\HeLa Cell Whole Genome Sequence (DNA or RNA)-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools and software needed to access or manipulate the shared scientific data include but are not limited to PacBio's SMRT Link for initial data processing, and potentially other bioinformatics packages like SAMtools and BWA for alignment and variant calling. These tools are widely used in the genomics community and can be accessed through their respective official websites or through containerization platforms like Docker.",ok
HeLa Cell Whole Genome Sequence (DNA or RNA),primary\llama-DMPs\HeLa Cell Whole Genome Sequence (DNA or RNA)-llama3.3.md,### Element 3: Standards:,"The project will apply common data standards to ensure interoperability of datasets. For genomic data, standards such as those provided by the Global Alliance for Genomics and Health (GA4GH) and the National Center for Biotechnology Information (NCBI) will be followed. Specifically, data will be formatted according to the SAM/BAM specification for aligned sequences and VCF for variant calls. Metadata will adhere to the MINSEQE guidelines where applicable, ensuring that all experimental and analytical processes are thoroughly documented and accessible.",ok
HeLa Cell Whole Genome Sequence (DNA or RNA),primary\llama-DMPs\HeLa Cell Whole Genome Sequence (DNA or RNA)-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,"The scientific data and associated metadata arising from this project will be archived in the National Center for Biotechnology Information (NCBI) database, specifically through the Sequence Read Archive (SRA) for raw sequencing data and potentially dbGaP or equivalent repositories for analyzed data, depending on the sensitivity and type of data generated.",ok
HeLa Cell Whole Genome Sequence (DNA or RNA),primary\llama-DMPs\HeLa Cell Whole Genome Sequence (DNA or RNA)-llama3.3.md,2. **How scientific data will be findable and identifiable:**,"Scientific data will be made findable and identifiable via accession numbers provided by the repository where the data are archived. Additionally, a persistent unique identifier (e.g., DOI) may be assigned to datasets upon publication, facilitating easy citation and access.",ok
HeLa Cell Whole Genome Sequence (DNA or RNA),primary\llama-DMPs\HeLa Cell Whole Genome Sequence (DNA or RNA)-llama3.3.md,3. **When and how long the scientific data will be made available:**,"The scientific data will be made available no later than the time of an associated publication or at the end of the performance period, whichever comes first. The data are expected to remain accessible indefinitely through the designated repositories, ensuring their availability for future research.",ok
HeLa Cell Whole Genome Sequence (DNA or RNA),primary\llama-DMPs\HeLa Cell Whole Genome Sequence (DNA or RNA)-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","Given that all research participants have been consented for broad data sharing, there are no anticipated limitations on the access, distribution, or reuse of the scientific data beyond standard considerations for genomic data, such as adherence to GA4GH guidelines and respect for the original consent provided by the participants.",ok
HeLa Cell Whole Genome Sequence (DNA or RNA),primary\llama-DMPs\HeLa Cell Whole Genome Sequence (DNA or RNA)-llama3.3.md,2. **Whether access to scientific data will be controlled:**,"Access to the scientific data will not be controlled beyond the standard access controls implemented by the repositories where the data are archived. This means that once deposited, the data will be freely accessible to all users of these public databases.",ok
HeLa Cell Whole Genome Sequence (DNA or RNA),primary\llama-DMPs\HeLa Cell Whole Genome Sequence (DNA or RNA)-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","Since the project involves sequencing data from a well-characterized cell line (HeLa), which is not considered personal identifiable information in this context, additional protections beyond standard repository access controls are not deemed necessary. However, all procedures will adhere to relevant guidelines and regulations regarding the use and sharing of human-derived cell lines.",ok
HeLa Cell Whole Genome Sequence (DNA or RNA),primary\llama-DMPs\HeLa Cell Whole Genome Sequence (DNA or RNA)-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be monitored and managed by the Principal Investigator (PI) of the project, in conjunction with the institution's research data management office. Regular checks will be performed at least bi-annually to ensure that all generated data are properly archived, documented, and shared according to the plan outlined here. Any issues or updates regarding data sharing will be addressed promptly by the PI in consultation with relevant stakeholders within the institution.",ok
Secondary Data Analysis on Data from Human Subjects-NIA,primary\llama-DMPs\Secondary Data Analysis on Data from Human Subjects-NIA-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"The proposed secondary analysis of publicly available datasets will generate several types of scientific data, including but not limited to, processed imaging data (BOLD signal, DTI indices such as fractional anisotropy, axial diffusivity, radial diffusivity, mean diffusivity), WM/GM connectivity maps derived from Fluorescence Optical Imaging (FOI) atlases in NIFTI format, and statistical analysis results comparing local anisotropic correlation of the BOLD signal and DTI indices between subjects with Alzheimer’s disease (AD) and those without AD. The estimated amount of data includes imaging datasets for 2,000 subjects (1,000 with AD and 1,000 without AD), which will be approximately 10 TB in size considering the high-resolution nature of MR and PET scans.",ok
Secondary Data Analysis on Data from Human Subjects-NIA,primary\llama-DMPs\Secondary Data Analysis on Data from Human Subjects-NIA-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All processed imaging data, statistical analysis results, and derived WM/GM connectivity maps will be preserved and shared. The rationale is to provide the research community with comprehensive datasets that can enhance understanding of white matter circuits in normal aging and AD, facilitate replication studies, and foster new investigations into the pathophysiology of AD.",ok
Secondary Data Analysis on Data from Human Subjects-NIA,primary\llama-DMPs\Secondary Data Analysis on Data from Human Subjects-NIA-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","Associated metadata will include subject demographics (age, sex), clinical and cognitive assessment scores, APOE status, and imaging protocol details. Other relevant data will comprise study protocols, data collection instruments, and detailed methodologies for image processing and statistical analyses. These will be made accessible to facilitate interpretation of the scientific data and ensure transparency and reproducibility.",ok
Secondary Data Analysis on Data from Human Subjects-NIA,primary\llama-DMPs\Secondary Data Analysis on Data from Human Subjects-NIA-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools and software needed to access or manipulate shared scientific data include FSL (FMRIB Software Library) for DTI analysis, AFNI (Analysis of Functional NeuroImages) for BOLD signal processing, and 3D Slicer for visualization and segmentation of imaging data. These tools are widely used in the neuroimaging community and can be accessed freely or through institutional licenses.",ok
Secondary Data Analysis on Data from Human Subjects-NIA,primary\llama-DMPs\Secondary Data Analysis on Data from Human Subjects-NIA-llama3.3.md,### Element 3: Standards:,"Common data standards to be applied include the NIfTI (Neuroimaging Informatics Technology Initiative) format for imaging data, ensuring interoperability across different analysis platforms. For metadata, standards such as those recommended by the NIH-funded Biomedical Data Sharing Workgroup will be followed, facilitating consistent description and annotation of datasets.",ok
Secondary Data Analysis on Data from Human Subjects-NIA,primary\llama-DMPs\Secondary Data Analysis on Data from Human Subjects-NIA-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,"The scientific data and associated metadata will be archived in the National Institutes of Health’s (NIH) National Library of Medicine (NLM) repository, specifically through the Open Access Series of Imaging Studies (OASIS) database for neuroimaging data, ensuring broad accessibility and long-term preservation.",ok
Secondary Data Analysis on Data from Human Subjects-NIA,primary\llama-DMPs\Secondary Data Analysis on Data from Human Subjects-NIA-llama3.3.md,2. **How scientific data will be findable and identifiable:**,"Data will be made findable and identifiable through the use of persistent unique identifiers (e.g., DOIs - Digital Object Identifiers), standard indexing tools, and detailed metadata descriptions uploaded to the repository and linked to relevant publications.",ok
Secondary Data Analysis on Data from Human Subjects-NIA,primary\llama-DMPs\Secondary Data Analysis on Data from Human Subjects-NIA-llama3.3.md,3. **When and how long the scientific data will be made available:**,"The scientific data will be made available no later than the time of publication of the primary results or within 12 months of the project’s completion, whichever comes first. Data will remain accessible for a minimum of 10 years after the project’s completion to accommodate potential future research needs and replication studies.",ok
Secondary Data Analysis on Data from Human Subjects-NIA,primary\llama-DMPs\Secondary Data Analysis on Data from Human Subjects-NIA-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","Given that all subjects have provided consent for broad data sharing, there are no anticipated limitations on access, distribution, or reuse beyond standard expectations for appropriate use in research contexts and compliance with applicable laws and regulations regarding human subject research.",ok
Secondary Data Analysis on Data from Human Subjects-NIA,primary\llama-DMPs\Secondary Data Analysis on Data from Human Subjects-NIA-llama3.3.md,2. **Whether access to scientific data will be controlled:**,"Access to the scientific data will not be controlled; once archived, data will be openly accessible without need for approval, aligning with principles of open science and maximizing the potential benefits of data sharing.",ok
Secondary Data Analysis on Data from Human Subjects-NIA,primary\llama-DMPs\Secondary Data Analysis on Data from Human Subjects-NIA-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","Although the primary datasets are publicly available and de-identified, any additional metadata or results that could potentially reveal subject identities will be protected through secure storage and access controls. De-identification procedures will follow HIPAA guidelines to ensure the privacy, rights, and confidentiality of human research participants are maintained.",ok
Secondary Data Analysis on Data from Human Subjects-NIA,primary\llama-DMPs\Secondary Data Analysis on Data from Human Subjects-NIA-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be monitored and managed by the Principal Investigator (PI) in collaboration with the institution’s Research Data Management Office. Regular oversight meetings will occur bi-annually to review data management practices, ensure adherence to the sharing plan, address any challenges or updates in data standards or policies, and maintain accurate records of data sharing activities.",ok
Analysis of social media posts,primary\llama-DMPs\Analysis of social media posts-llama3.3.md,1. **Types and amount of scientific data expected to be generated in the project:**,"The proposed study is expected to generate several types of scientific data, including: 
     - Approximately 300,000 publicly available social media posts (including images and videos) with associated comments.
     - Quantitative survey data from 500 young adult participants (age 18-34).
     - User analytics such as views, comments, and shares from the intervention delivered via Instagram.
   The total estimated amount of data is substantial, given the volume of social media posts, survey responses, and user analytics metrics.",ok
Analysis of social media posts,primary\llama-DMPs\Analysis of social media posts-llama3.3.md,"2. **Scientific data that will be preserved and shared, and the rationale for doing so:**","All collected scientific data (social media posts with comments, survey data, and user analytics) will be preserved and shared because they are essential for understanding the impact of social media on young adults' perceptions and behaviors related to cancer. Sharing these data will enable other researchers to replicate findings, conduct secondary analyses, and advance our understanding of how social media influences health outcomes.",ok
Analysis of social media posts,primary\llama-DMPs\Analysis of social media posts-llama3.3.md,"3. **Metadata, other relevant data, and associated documentation:**","The following metadata and documentation will be made accessible:
     - Study protocols.
     - Data collection instruments (e.g., survey questions).
     - Data dictionaries describing variable names, definitions, and codes used for categorizing social media posts.
     - Documentation of data processing steps, including how identifiers were removed and how missing values were handled.
     - Intervention group assignments for participants.",ok
Analysis of social media posts,primary\llama-DMPs\Analysis of social media posts-llama3.3.md,"### Element 2: Related Tools, Software and/or Code:","Specialized tools and software are needed to access or manipulate the shared scientific data. Specifically, tools for data mining (for social media posts), statistical analysis software (e.g., R, SPSS, SAS) for survey data and user analytics, and potentially machine learning libraries for sentiment analysis or topic modeling of social media content. These tools can be accessed through academic licenses or open-source repositories.",ok
Analysis of social media posts,primary\llama-DMPs\Analysis of social media posts-llama3.3.md,### Element 3: Standards:,"To enable interoperability, the following common data standards will be applied:
     - For social media posts, a standardized schema for metadata (e.g., date posted, engagement metrics) and content analysis (e.g., sentiment, topic codes).
     - For survey data, adherence to Questionnaire Design principles and use of standardized demographic categories.
     - For user analytics, metrics will follow the standards set by the social media platform (Instagram) for views, comments, shares, etc.
   These standards facilitate comparison across datasets and ensure that the scientific community can easily understand and build upon the research findings.",ok
Analysis of social media posts,primary\llama-DMPs\Analysis of social media posts-llama3.3.md,1. **Repository where scientific data and metadata will be archived:**,The scientific data and associated metadata arising from this project will be archived in the National Cancer Institute's (NCI) Genomic Data Commons (GDC) or a similar NIH-approved repository that aligns with the data types collected.,ok
Analysis of social media posts,primary\llama-DMPs\Analysis of social media posts-llama3.3.md,2. **How scientific data will be findable and identifiable:**,"Scientific data will be made findable through the use of persistent unique identifiers (e.g., DOIs for datasets, publications) and standard indexing tools such as PubMed for publications resulting from the data analysis.",ok
Analysis of social media posts,primary\llama-DMPs\Analysis of social media posts-llama3.3.md,3. **When and how long the scientific data will be made available:**,"The scientific data will be made available no later than the time of publication of the main findings or at the end of the performance period, whichever comes first. Data will remain available indefinitely through the chosen repository, in accordance with NIH policies on data sharing.",ok
Analysis of social media posts,primary\llama-DMPs\Analysis of social media posts-llama3.3.md,"1. **Factors affecting subsequent access, distribution, or reuse of scientific data:**","The primary factor affecting access is the protection of human subjects' privacy and confidentiality. Given that all data will be deidentified and participants have consented to broad data sharing, no additional limitations on access are anticipated beyond those standard protections for human subject research.",ok
Analysis of social media posts,primary\llama-DMPs\Analysis of social media posts-llama3.3.md,2. **Whether access to scientific data will be controlled:**,Access to the scientific data will not be controlled beyond the standard measures applied by the repository for ensuring that users agree to terms of use that respect privacy and confidentiality protections.,ok
Analysis of social media posts,primary\llama-DMPs\Analysis of social media posts-llama3.3.md,"3. **Protections for privacy, rights, and confidentiality of human research participants:**","To protect the privacy, rights, and confidentiality of human research participants:
     - All identifying information (names, social media handles) will be removed from social media posts and comments.
     - Survey data and user analytics will be deidentified upon collection.
     - The study has obtained or will obtain a Certificate of Confidentiality to further protect sensitive information.",ok
Analysis of social media posts,primary\llama-DMPs\Analysis of social media posts-llama3.3.md,### Element 6: Oversight of Data Management and Sharing:,"Compliance with this Data Management and Sharing Plan will be monitored and managed by the Principal Investigator (PI) in collaboration with the data manager and other key personnel. Regular checks (every 6 months) will ensure that data are being properly collected, stored, and prepared for sharing according to the plan. The PI is responsible for reporting any issues or deviations from the plan to the NIH and for ensuring that all team members understand their roles in data management and sharing.",ok
